



FORM PTO - 1449

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT

ATTORNEY DOCKET NO.: LEX-004C1

APPLICANT(S): Gillies

SERIAL NO.: 10/714,165 CONF. NO.: 2258

FILING DATE: November 14, 2003 GROUP: 1641

U.S. PATENT DOCUMENTS

| EXAM. INIT. | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
|----------------|------|--------------------|----------|-------------------------|-------|--------------|----------------------------------|
| POT | A111 | 4,469,797 | 9/4/84 | Albarella | | | |
| | A112 | 4,816,567 | 3/28/89 | Cabilly <i>et al.</i> | | | |
| | A113 | 4,946,778 | 8/7/90 | Ladner <i>et al.</i> | | | |
| | A114 | 4,975,369 | 12/4/90 | Beavers <i>et al.</i> | | | |
| | A115 | 5,019,368 | 5/28/91 | Epstein <i>et al.</i> | | | |
| | A116 | 5,225,539 | 7/6/93 | Winter | | | |
| | A117 | 5,349,053 | 9/20/94 | Landolfi | | | |
| | A118 | 5,480,981 | 1/2/96 | Goodwin <i>et al.</i> | | | |
| | A119 | 5,585,089 | 12/17/96 | Queen <i>et al.</i> | | | |
| | A120 | 5,609,846 | 3/11/97 | Goldenberg | | | |
| | A121 | 5,614,184 | 3/25/97 | Sytkowski <i>et al.</i> | | | |
| | A122 | 5,650,150 | 7/22/97 | Gillies | | | |
| | A123 | 5,679,543 | 10/21/97 | Lawlis | | | |
| | A124 | 5,709,859 | 1/20/98 | Aruffo <i>et al.</i> | | | |
| | A125 | 5,712,120 | 1/27/98 | Rodriguez <i>et al.</i> | | | |
| | A126 | 5,723,125 | 3/3/98 | Chang <i>et al.</i> | | | |
| | A127 | 5,726,044 | 3/10/98 | Lo <i>et al.</i> | | | |
| | A128 | 5,728,552 | 3/17/98 | Fujisawa <i>et al.</i> | | | |
| | A129 | 5,770,195 | 6/23/98 | Hudziak <i>et al.</i> | | | |
| | A130 | 5,807,715 | 9/15/98 | Morrison <i>et al.</i> | | | |
| | A131 | 5,827,516 | 10/27/98 | Urban <i>et al.</i> | | | |
| | A132 | 5,827,703 | 10/27/98 | Debs <i>et al.</i> | | | |
| | A133 | 5,837,821 | 11/17/98 | Wu <i>et al.</i> | | | |
| | A134 | 5,843,423 | 12/1/98 | Lyman <i>et al.</i> | | | |
| | A135 | 5,888,773 | 3/30/99 | Jost <i>et al.</i> | | | |
| | A136 | 5,908,626 | 6/1/99 | Chang <i>et al.</i> | | | |

EXAMINER

DATE CONSIDERED

2/1/6

| FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT | | | | ATTORNEY DOCKET NO.: LEX-004C1 APPLICANT(S): Gillies SERIAL NO.: 10/714,165 CONF. NO.: 2258 FILING DATE: November 14, 2003 GROUP: 1641 | | | |
|---|------|--------------------|----------|---|-------|--------------|----------------------------------|
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAM. INIT. | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
| P6T | A137 | 6,086,875 | 7/11/00 | Blumberg <i>et al.</i> | | | |
| | A138 | 6,100,387 | 8/8/00 | Herrmann <i>et al.</i> | | | |
| | A139 | 6,169,070 | 1/2/01 | Chen <i>et al.</i> | | | |
| | A140 | 6,291,158 | 9/18/01 | Winter <i>et al.</i> | | | |
| | A141 | 6,335,176 | 1/1/02 | Inglese <i>et al.</i> | | | |
| | A142 | 6,335,176 | 01/01/02 | Inglese <i>et al.</i> | | | |
| | A143 | 6,444,792 | 9/3/02 | Gray <i>et al.</i> | | | |
| | A144 | 6,475,717 | 11/5/02 | Enssle <i>et al.</i> | | | |
| | A145 | 6,485,726 | 11/26/02 | Blumberg <i>et al.</i> | | | |
| | A146 | 6,500,641 | 12/31/02 | Chen <i>et al.</i> | | | |
| | A147 | 6,551,592 | 4/22/03 | Lindhofer <i>et al.</i> | | | |
| | A148 | 6,617,135 | 9/9/03 | Gillies <i>et al.</i> | | | |
| | A149 | 6,620,413 | 09/16/03 | DeSavage <i>et al.</i> | | | |
| | A150 | 6,627,615 | 9/30/03 | Debs <i>et al.</i> | | | |
| | A151 | 6,646,113 | 11/11/03 | Dreyfuss <i>et al.</i> | | | |
| | A152 | 6,750,329 | 6/15/04 | Rosenblum <i>et al.</i> | | | |
| | A153 | 6,838,260 | 01/04/05 | Gillies <i>et al.</i> | | | |
| | A154 | 2003/0105294 | 6/5/03 | Gillies <i>et al.</i> | | | |
| | A155 | 2003/0139365 | 7/24/03 | Lo <i>et al.</i> | | | |
| | A156 | 2003/0139575 | 7/24/03 | Gillies | | | |
| | A157 | 2003/0157054 | 8/21/03 | Gillies <i>et al.</i> | | | |
| | A158 | 2003/0166163 | 9/4/03 | Gillies | | | |
| | A159 | 2003/0166877 | 9/4/03 | Gillies <i>et al.</i> | | | |
| | A160 | 2004/0033210 | 2/19/04 | Gillies | | | |
| | A161 | 2004/0043457 | 3/4/04 | Schumacher <i>et al.</i> | | | |
| | A162 | 2004/0053366 | 3/18/04 | Lo <i>et al.</i> | | | |
| EXAMINER P6C | | | | DATE CONSIDERED 2/1/6 | | | |

| FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT | | | | ATTORNEY DOCKET NO.: LEX-004C1 APPLICANT(S): Gillies SERIAL NO.: 10/714,165 CONF. NO.: 2258 FILING DATE: November 14, 2003 GROUP: 1641 | | | |
|---|------|--------------------|----------|---|-------|--------------|----------------------------------|
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAM. INIT. | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
| PBT | A163 | 2004/0072299 | 4/15/04 | Gillies <i>et al.</i> | | | |
| | A164 | 2004/0082039 | 4/29/04 | Gillies <i>et al.</i> | | | |
| | A165 | 2004/0180386 | 9/16/04 | Carr <i>et al.</i> | | | |
| | A166 | 2004/0203100 | 10/14/04 | Gillies <i>et al.</i> | | | |
| | A167 | 2005/0069521 | 03/31/05 | Gillies <i>et al.</i> | | | |

| | | | |
|----------|-----|-----------------|-------|
| EXAMINER | PBT | DATE CONSIDERED | 2/1/6 |
|----------|-----|-----------------|-------|

| FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT | | | | | ATTORNEY DOCKET NO.: LEX-004C1 APPLICANT(S): Gillies SERIAL NO.: 10/714,165 CONF. NO.: 2258 FILING DATE: November 14, 2003 GROUP: 1641 | | | | |
|---|------|--------------------|----------|-----------------|---|--------------|----------------|------------------|--------------------------|
| FOREIGN PATENT DOCUMENTS | | | | | | | | | |
| EXAM INIT. | | DOCUMENT NUMBER | DATE | COUNTRY CODE | CLASS | SUB CLASS | FILING DATE | ABSTRACT ONLY | ENGLISH LANG (Y/N) |
| Pkt | B108 | 0 294 703 A2 | 12/14/88 | EP | | | | | Y |
| | B109 | 0 308 936 B1 | 3/29/89 | EP | | | | | Y |
| | B110 | 0 314 317 B1 | 5/3/89 | EP | | | | | Y |
| | B111 | 0 318 554 B1 | 6/7/89 | EP | | | | | Y |
| | B112 | 0 326 120 B1 | 8/2/89 | EP | | | | | Y |
| | B113 | 0 344 134 B1 | 01/19/94 | EP | | | | | Y |
| | B114 | 0 350 230 A2 | 1/10/90 | EP | | | | | Y |
| | B115 | 0 375 562 B1 | 6/27/90 | EP | | | | | Y |
| | B116 | 0 396 387 A2 | 11/7/90 | EP | | | | | Y |
| | B117 | 0 428 596 B1 | 4/17/96 | EP | | | | | Y |
| | B118 | 0 439 095 A2 | 7/31/91 | EP | | | | | Y |
| | B119 | 0 511 747 A1 | 11/4/92 | EP | | | | | Y |
| | B120 | 0 519 596 A1 | 13/32/92 | EP | | | | | Y |
| | B121 | 0 601 043 B1 | 6/15/94 | EP | | | | | Y |
| | B122 | 0 699 755 A2 | 3/6/96 | EP | | | | | Y |
| | B123 | 0 706 799 A2 | 4/17/96 | EP | | | | | Y |
| | B124 | 1 088 888 A1 | 4/4/01 | EP | | | | | Y |
| | B125 | 21725/88 | 3/23/89 | AU | | | | | Y |
| | B126 | 2 188 638 | 10/7/87 | GB | | | | | Y |
| | B127 | WO 86/01533 | 3/13/86 | PCT | | | | | Y |
| | B128 | WO 88/00052 | 1/14/88 | PCT | | | | | Y |
| | B129 | WO 88/09344 | 12/1/88 | PCT | | | | | Y |

EXAMINER

Pb mg

DATE CONSIDERED

2/1/06

| FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT | | | | | ATTORNEY DOCKET NO.: LEX-004C1 APPLICANT(S): Gillies SERIAL NO.: 10/714,165 CONF. NO.: 2258 FILING DATE: November 14, 2003 GROUP: 1641 | | | | |
|---|------|--------------------|----------|-----------------|---|--------------|----------------|------------------|--------------------------|
| FOREIGN PATENT DOCUMENTS | | | | | | | | | |
| EXAM INIT. | | DOCUMENT NUMBER | DATE | COUNTRY CODE | CLASS | SUB CLASS | FILING DATE | ABSTRACT ONLY | ENGLISH LANG (Y/N) |
| P05 | B130 | WO 89/02922 | 4/6/89 | PCT | | | | | Y |
| | B131 | WO 89/09620 | 10/19/89 | PCT | | | | Y | Y |
| | B132 | WO 91/00360 | 1/10/91 | PCT | | | | | Y |
| | B133 | WO 91/04329 | 04/04/91 | PCT | | | | | Y |
| | B134 | WO 91/08298 | 6/13/91 | PCT | | | | | Y |
| | B135 | WO 91/13166 | 9/5/91 | PCT | | | | | Y |
| | B136 | WO 91/14438 | 10/3/91 | PCT | | | | | Y |
| | B137 | WO 92/02240 | 2/20/92 | PCT | | | | | Y |
| | B138 | WO 92/08495 | 5/29/92 | PCT | | | | | Y |
| | B139 | WO 92/08801 | 5/29/92 | PCT | | | | | Y |
| | B140 | WO 92/10755 | 6/25/92 | PCT | | | | | Y |
| | B141 | WO 92/16562 | 10/1/92 | PCT | | | | | Y |
| | B142 | WO 93/03157 | 2/18/93 | PCT | | | | | Y |
| | B143 | WO 94/25609 | 11/10/94 | PCT | | | | | Y |
| | B144 | WO 95/05468 | 2/23/95 | PCT | | | | | Y |
| | B145 | WO 95/21258 | 8/10/95 | PCT | | | | | Y |
| | B146 | WO 95/31483 | 11/23/95 | PCT | | | | | Y |
| | B147 | WO 96/04388 | 02/15/96 | PCT | | | | | Y |
| | B148 | WO 96/08570 | 3/21/96 | PCT | | | | | Y |
| | B149 | WO 96/18412 | 6/20/96 | PCT | | | | | Y |
| | B150 | WO 96/40792 | 12/19/96 | PCT | | | | | Y |
| | B151 | WO 97/00317 | 1/3/97 | PCT | | | | | Y |
| | B152 | WO 97/00319 | 1/3/97 | PCT | | | | | Y |

EXAMINER

P6C7

DATE CONSIDERED

2/1/6

| FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT | | | | | ATTORNEY DOCKET NO.: LEX-004C1 APPLICANT(S): Gillies SERIAL NO.: 10/714,165 CONF. NO.: 2258 FILING DATE: November 14, 2003 GROUP: 1641 | | | | |
|---|------|--------------------|----------|-----------------|---|--------------|----------------|------------------|--------------------------|
| FOREIGN PATENT DOCUMENTS | | | | | | | | | |
| EXAM INIT. | | DOCUMENT NUMBER | DATE | COUNTRY CODE | CLASS | SUB CLASS | FILING DATE | ABSTRACT ONLY | ENGLISH LANG (Y/N) |
| POT | B153 | WO 97/24137 | 7/10/97 | PCT | | | | | Y |
| | B154 | WO 97/24440 | 7/10/97 | PCT | | | | | Y |
| | B155 | WO 97/30089 | 8/21/97 | PCT | | | | | Y |
| | B156 | WO 97/33617 | 9/18/97 | PCT | | | | | Y |
| | B157 | WO 97/33619 | 9/18/97 | PCT | | | | | Y |
| | B158 | WO 97/34631 | 9/25/97 | PCT | | | | | Y |
| | B159 | WO 97/43316 | 11/20/97 | PCT | | | | | Y |
| | B160 | WO 98/00127 | 1/8/98 | PCT | | | | | Y |
| | B161 | WO 98/28427 | 7/2/98 | PCT | | | | | Y |
| | B162 | WO 98/30706 | 7/16/98 | PCT | | | | | Y |
| | B163 | WO 98/46257 | 10/22/98 | PCT | | | | | Y |
| | B164 | WO 98/52976 | 11/26/98 | PCT | | | | | Y |
| | B165 | WO 98/59244 | 12/30/98 | PCT | | | | | Y |
| | B166 | WO 99/02709 | 01/21/99 | PCT | | | | | Y |
| | B167 | WO 99/03887 | 01/28/99 | PCT | | | | | Y |
| | B168 | WO 99/29732 | 6/17/99 | PCT | | | | | Y |
| | B169 | WO 99/43713 | 9/2/99 | PCT | | | | | Y |
| | B170 | WO 99/52562 | 10/21/99 | PCT | | | | | Y |
| | B171 | WO 00/01822 | 1/13/00 | PCT | | | | | Y |
| | B172 | WO 00/34317 | 06/15/00 | PCT | | | | | Y |
| | B173 | WO 02/079232 | 10/10/02 | PCT | | | | | Y |

| | |
|----------------------|-------------------------------|
| EXAMINER: <i>POT</i> | DATE CONSIDERED: <i>2/1/6</i> |
|----------------------|-------------------------------|

| | | |
|---|--|---|
| FORM PTO - 1449 | | ATTORNEY DOCKET NO.: LEX-004C1 |
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT | | APPLICANT(S): Gillies |
| | | SERIAL NO.: 10/714,165 CONF. NO.: 2258 |
| | | FILING DATE: November 14, 2003 GROUP: 1641 |
| OTHER ART, JOURNAL ARTICLES, ETC. | | |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | |
| P6T | C262 | Adkins et al., (1998), "Edrecolomab (Monoclonal Antibody 17-1A)," Drugs, 56(4):619-626. |
| | C263 | Anderson et al., (1980), "Characterization of the Fc Receptor for IgG on a Human Macrophage Cell Line U937," J. Immunol., 125(6):2735-41. |
| | C264 | Baici et al., (1980), "Kinetics of the Different Susceptibilities of the Four Human Immunoglobulin G Subclasses to Proteolysis by Human Lysosomal Elastase," Scand. J. Immunol. 12(1):41-50. |
| | C265 | Boulianne et al., (1984), "Production of Functional Chimaeric Mouse/Human Antibody," Nature, 312:643-6. |
| | C266 | Bourgeois et al., (1974), "Determination of the Primary Structure of a Mouse IgG2a Immunoglobulin: Amino-Acid Sequence of the Fc Fragment: Implications for the Evolution of Immunoglobulin Structure and Function," Eur. J. Biochem., 43:423-35. |
| | C267 | Brambell et al., (1964), "A Theoretical Model of γ -Globulin Catabolism," Nature, 203:1352-55. |
| | C268 | Brekke et al., (1994), "Human IgG Isotype-Specific Amino Acid Residues Affecting Complement-Mediated Cell Lysis and Phagocytosis," Eur. J. Immunol., 24:2542-2547. |
| | C269 | Bubenik et al., (1995), "Interleukin-2 Gene Therapy of Residual EL-4 Leukaemia Potentiates the Effect of Cyclophosphamide Pretreatment," J. Cancer Res. Clin. Oncol., 121:39-43. |
| | C270 | Chan et al., (1992), "Mechanisms of IFN- γ Induction by Natural Killer Cell Stimulatory Factor (NKSF/IL-12). Role of Transcription and mRNA Stability in the Synergistic Interaction Between NKSF and IL-2," J. Immunol., 148:92-98. |
| | C271 | Chappel et al., (1991), "Identification of the Fc Gamma Receptor Class I Binding Site In Human IgG Through Use of Recombinant IgG1/IgG2 Hybrid and Point-Mutated Antibodies," Proc. Natl. Acad. Sci. USA, 88(20):9036-40. |
| | C272 | Cirulli et al., (1998), "KSA Antigen Ep-CAM Mediates Cell-Cell Adhesion of Pancreatic Epithelial Cells: Morphoregulatory Roles in Pancreatic Islet Development," J. Cell Biol., 140:1519-34. |
| | C273 | Cohen et al., (1998), "An Artificial Cell-Cycle Inhibitor Isolated from a Combinatorial Library," Proc. Natl. Acad. Sci. USA, 95:14272-7. |
| | C274 | Ellison et al., (1982), "The Nucleotide Sequence of a Human Immunoglobulin C γ 1 Gene," Nucleic Acids Res., 10:4071-9. |
| | C275 | Ghetie et al., (1997), "FcRn: The MHC Class I-Related Receptor that is More Than an IgG Transporter," Immunology Today, 18(12):592-598. |

| | | | |
|----------|-----|-----------------|-------|
| EXAMINER | P6T | DATE CONSIDERED | 2/1/6 |
|----------|-----|-----------------|-------|

| | | | |
|---|--|--|--|
| FORM PTO - 1449 | | ATTORNEY DOCKET NO.: LEX-004C1 | |
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT | | APPLICANT(S): Gillies | |
| | | SERIAL NO.: 10/714,165 CONF. NO.: 2258 | |
| | | FILING DATE: November 14, 2003 GROUP: 1641 | |
| OTHER ART, JOURNAL ARTICLES, ETC. | | | |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| P05 | C276 | Gurewich et al., (1988), "Characterization of the Intrinsic Fibrinolytic Properties of Pro-Urokinase Through a Study of Plasmin-Resistant Mutant Forms Produced by Site-Specific Mutagenesis of Lysine," J. Clin. Invest., 82:1956-1962. | |
| | C277 | Hornick et al., (1999), "Pretreatment with a Monoclonal Antibody/Interleukin-2 Fusion Protein Directed Against DNA Enhances the Delivery of Therapeutic Molecules to Solid Tumors," Clin. Cancer Research, 5:51-60. | |
| | C278 | Hulett et al., (1994), "Molecular Basis of Fc Receptor Function," Adv. Immunol., 57:1127. | |
| | C279 | Hurn et al., (1980), "Production of Reagent Antibodies," Methods in Enzymology, 70: 104-142. | |
| | C280 | Huston et al., (1988), "Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced In Escherichia Coli," Proc. Natl. Acad. Sci. USA, 85:5879-5883. | |
| | C281 | Isaacs et al., (1998), "Therapy with Monoclonal Antibodies. II. The Contribution of Fcγ Receptor Binding and the Influence of CH1 and CH3 Domains on In Vivo Effector Function," J. Immunol., 161:3862-3869. | |
| | C282 | Jefferis et al., (1990), "Molecular Definition of Interaction Sites on Human IgG for Fc Receptors huFcγR," Mol. Immunol., 27(12):1237-1240. | |
| | C283 | Lanza et al., (1993), "Active Immunity against the CD4 Receptor by Using an Antibody Antigenized with Residues 41-55 of the First Extracellular Domain," Proc. Natl. Acad. Sci. USA, 90:11683-7. | |
| | C284 | MacLean et al., (1996), "Enhancing the Effect of Theratope STn-KLH Cancer Vaccine in Patients with Metastatic Breast Cancer by Pretreatment with Low-Dose Intravenous Cyclophosphamide," J. Immunother., 19(4):309-316. | |
| | C285 | Mariani et al., (1997), "Tumor Targeting Potential of the Monoclonal Antibody BC-1 against Oncofetal Fibronectin in Nude Mice Bearing Human Tumor Implants," Cancer, 80:2378-84. | |
| | C286 | Martin et al., (2001), "Crystal Structure at 2.8 Å of an FcRn/Heterodimeric Fc Complex: Mechanism of pH-Dependent Binding," Mol. Cell., 7(4):867-77. | |
| | C287 | Mateo et al., (2000), "Removal of Amphipathic Epitopes from Genetically Engineered Antibodies: Production of Modified Immunoglobulins with Reduced Immunogenicity," Hybridoma, 19(6):463-471. | |
| | C288 | McMahan et al., (1991), "A Novel IL-1 Receptor, Cloned From B-Cells by Mammalian Expression is Expressed in Many Cell Types," EMBO J., 10:2821-32. | |
| | C289 | Menard et al., (1983), "Generation of Monoclonal Antibodies Reacting with Normal and Cancer Cells of Human Breast," Cancer Res., 43:1295-300. | |
| | C290 | Miyake et al., (1988), "Synthesis of Recombinant Human Single-Chain Urokinase-Type Plasminogen Activator Variants Resistant to Plasmin and Thrombin," J. Biochem., 104:643-647. | |
| EXAMINER | | DATE CONSIDERED | |
| P05 | | 2/1/6 | |

| | | | |
|---|--|--|--|
| FORM PTO - 1449 | | ATTORNEY DOCKET NO.: LEX-004C1 | |
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT | | APPLICANT(S): Gillies | |
| | | SERIAL NO.: 10/714,165 CONF. NO.: 2258 | |
| | | FILING DATE: November 14, 2003 GROUP: 1641 | |
| OTHER ART, JOURNAL ARTICLES, ETC. | | | |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| Pb | C291 | Morrison et al., (1984), "Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region Domains," Proc. Natl. Acad. Sci. USA, 81:6851-5. | |
| | C292 | Nastala et al., (1994), "Recombinant IL-12 Administration Induces Tumor Regression in Association with IFN- γ Production," J. Immunol., 153:1697-706. | |
| | C293 | Neal et al., (2003), "NXS2 Murine Neuroblastomas Express Increased Levels of MHC Class I Antigens upon Recurrence Following NK-Dependent Immunotherapy," Cancer Immunol. Immunother., 53:41-52. | |
| | C294 | Nelles et al., (1987), "Characterization of Recombinant Human Single Chain Urokinase-Type Plasminogen Activator Mutants Produced by Site-Specific Mutagenesis of Lysine 158," J. Biol. Chem., 262(12):5682-5689. | |
| | C295 | Orlandi et al., (1989), "Cloning Immunoglobulin Variable Domains for Expression by the Polymerase Chain Reaction," Proc. Natl. Acad. Sci. USA, 86:3833-7. | |
| | C296 | Pedley et al. (1999), "Enhancement of Antibody-Directed Enzyme Prodrug Therapy in Colorectal Xenografts by an Antivascular Agent," Cancer Res., 59:3998-4003. | |
| | C297 | Poon et al., (1995), "Structure and Function of Several Anti-Dansyl Chimeric Antibodies Formed by Domain Interchanges Between Human IgM and Mouse IgG2b," J. Biol. Chem., 270:8571-7. | |
| | C298 | Queen et al., (1989), "A Humanized Antibody that Binds to the Interleukin 2 Receptor," Proc. Natl. Acad. Sci. USA, 86:10029-33. | |
| | C299 | Riechmann et al., (1988), "Reshaping Human Antibodies for Therapy," Nature, 332:323-7. | |
| | C300 | Robinson et al., (1998), "Optimizing the Stability of Single-Chain Proteins by Linker Length and Composition Mutagenesis," Proc. Natl. Acad. Sci. USA, 95:5929-34. | |
| | C301 | Sakano et al., (1980), "Two Types of Somatic Recombination are Necessary for the Generation of Complete Immunoglobulin Heavy-Chain Genes," Nature, 286:676-683. | |
| | C302 | Schwartzberg et al., (2001), "Clinical Experience with Edrecolomab: A Monoclonal Antibody Therapy for Colon Carcinoma," Critical Reviews in Oncology/Hematology, 40:17-24. | |
| | C303 | Senior et al., (2000), "Cleavage of a Recombinant Human Immunoglobulin A2 (IgA2)-IgA1 Hybrid Antibody by Certain Bacterial IgA1 Proteases," Infect. Immun., 68(2):463-9. | |
| | C304 | Sharp et al., (1988), "Codon Usage Patterns in Escherichia coli, Bacillus subtilis, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Drosophila melanogaster and Homo sapiens; a Review of the Considerable Within-Species Diversity," Nucleic Acids Res., 16(17):8207-8211. | |
| | C305 | Takai, (2002), "Roles of Fc Receptors in Autoimmunity," Nat. Rev. Immunol., 2(8):580-92. | |

| | | | |
|----------|---------|-----------------|--------|
| EXAMINER | Pb (Vg) | DATE CONSIDERED | 2/1/06 |
|----------|---------|-----------------|--------|

| | | | |
|---|--|---|--|
| FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT | | ATTORNEY DOCKET NO.: LEX-004C1 APPLICANT(S): Gillies SERIAL NO.: 10/714,165 CONF. NO.: 2258 FILING DATE: November 14, 2003 GROUP: 1641 | |
| OTHER ART, JOURNAL ARTICLES, ETC. | | | |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| P169 | C306 | Tiruppathi et al., (1996), "Isolation and Characterization of a Cell Surface Albumin-Binding Protein from Vascular Endothelial Cells," Proc. Nat. Acad. Sci. USA, 93:250-4. | |
| | C307 | Voest et al., (1995), "Inhibition of Angiogenesis in Vivo by Interleukin 12," J. Natl. Canc. Inst., 87:581-6. | |
| | C308 | Ward et al., (1995), "The Effector Functions of Immunoglobulins: Implications for Therapy," Therapeutic Immunology, 2:77-94. | |
| | C309 | Weber et al., (2001), "Phase I Trial of huKS-IL2 Immunocytokine in Patients with Prostate Carcinoma: Clinical, PK, and Biological PD Results (Abstract)," American Society of Clinical Oncology Program/Proceedings, 20(Part 1):259a. | |
| | C310 | Weitkamp et al., (1973), "Additional Data on the Population Distribution of Human Serum Albumin Genes; Three New Variants," Ann. Hum. Genet., 37:219-26. | |
| | C311 | Wells, (1990), "Additivity of Mutational Effect in Proteins," Biochemistry, 29(37):8509-8517. | |
| | C312 | Woof et al., (1986), "Localisation of the Monocyte-Binding Region on Human Immunoglobulin G," Mol. Immunol., 23:319-30. | |
| | C313 | Wysocka et al., (1995), "Interleukin-12 is Required for Interferon- γ Production and Lethality in Lipopolysaccharide-Induced Shock in Mice," Eur. J. Immunol., 25:672-6. | |
| | C314 | Xu et al., (1994), "Residue at Position 331 in the IgG1 and IgG4 CH2 Domains Contributes to Their Differential Ability to Bind and Activate Complement," J. Biol. Chem., 269(5):3469-3474. | |
| | C315 | Yan et al., (1996), "Characterization of an Ig VH Idiotope that Results in Specific Homophilic Binding and Increased Avidity for Antigen," J. Immunol., 157:1582-8. | |
| | C316 | Yeh et al., (1992), "Design of Yeast-Secreted Albumin Derivatives for Human Therapy: Biological and Antiviral Properties of a Serum Albumin-CD4 Genetic Conjugate," Proc. Natl. Acad. Sci. USA, 89:1904-8. | |
| | C317 | Yu et al., (1998), "Phase I Trial of a Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 in Patients with Refractory Neuroblastoma and Osteosarcoma," J. Clinical Oncology, 16(6):2169-80. | |
| | C318 | Zhu et al., (2001), "MHC Class I-Related Neonatal Fc Receptor for IgG is Functionally Expressed in Monocytes, Intestinal Macrophages and Dendritic Cells," J. Immunol., 166:3266-3276. | |
| | C319 | Zuckier et al., (1998), "Chimeric Human-Mouse IgG Antibodies with Shuffled Constant Region Exons Demonstrate that Multiple Domains Contribute to In Vivo Half-Life," Cancer Res., 58(17):3905-8. | |


BOS-875135 v1

| | | | |
|----------|------|-----------------|-------|
| EXAMINER | P169 | DATE CONSIDERED | 2/1/6 |
|----------|------|-----------------|-------|



| FORM PTO - 1449 | | | | ATTORNEY DOCKET NO.: LEX-004C1 | | | | | |
|---|--|--|----------|--|-----------------|-----------|----------------------------|---------------|--------------------|
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT | | | | APPLICANT: Gillies | | | | | |
| | | | | SERIAL NO.: 10/714,165 | | | | | |
| | | | | FILING DATE: November 14, 2003 GROUP: 1641 | | | | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | |
| EXAM. INIT. | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE | | |
| P65 | A97 | 5,601,819 | 2/11/97 | Wong et al. | | | | | |
| | A98 | 5,891,680 | 4/6/99 | Lieschke et al. | | | | | |
| | A99 | 5,994,104 | 11/30/99 | Anderson et al. | | | | | |
| | A100 | 6,429,199 | 8/6/02 | Krieg et al. | | | | | |
| | A101 | 6,551,592 | 4/22/03 | Lindhofer et al. | | | | | |
| | A102 | 6,646,113 | 11/11/03 | Dreyfuss et al. | | | | | |
| | A103 | 2002/0037558 | 3/28/02 | Lo et al. | | | | | |
| | A104 | 2002/0146388 | 10/10/02 | Gillies | | | | | |
| | A105 | 2003/0139365 | 7/24/03 | Lo et al. | | | | | |
| | A106 | 2003/0139575 | 7/24/03 | Gillies | | | | | |
| | A107 | 2004/0033210 | 2/19/04 | Gillies | | | | | |
| | A108 | 2004/0053366 | 3/18/04 | Lo et al. | | | | | |
| | A109 | 2004/0072299 | 4/15/04 | Gillies et al. | | | | | |
| | A110 | 2004/0082039 | 4/29/04 | Gillies et al. | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | |
| EXAM. INIT. | | DOCUMENT NUMBER | DATE | COUNTRY CODE | CLASS | SUB CLASS | FILING DATE | ABSTRACT ONLY | ENGLISH LANG (Y/N) |
| P65 | B107 | WO 93/20185 | 10/14/93 | PCT | | | | | |
| OTHER ART, JOURNAL ARTICLES, ETC. | | | | | | | | | |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | | | | | | | |
| P65 | C239 | Chapman et al., (1994), "Mapping Effector Functions of a Monoclonal Antibody to GD3 by Characterization of a Mouse-Human Chimeric Antibody," <u>Cancer Immuno. Immunother.</u> , 39:198-204. | | | | | | | |
| | C240 | Cruse et al., (eds.), (1995), <u>Illustrated Dictionary of Immunology</u> , p.158, CRC Press, NY. | | | | | | | |
| | C241 | de la Salle et al., (1996), "FcγR on Human Dendritic Cells," in <u>Human IgG Receptors</u> , pp. 39-55, van de Winkel et al. (eds.), R.G. Landes Co. | | | | | | | |
| EXAMINER | | | | | DATE CONSIDERED | | | | |
| P65 | | | | | 2/1/6 | | | | |


| | | | |
|--|--|--|-----------------------|
| FORM PTO - 1449 | | ATTORNEY DOCKET NO.: LEX-004C1 | |
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT | | APPLICANT: Gillies | |
| | | SERIAL NO.: 10/714,165 | |
| | | FILING DATE: November 14, 2003 GROUP: 1641 | |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| PbT | C242 | Dorai et al., (1991), "Aglycosylated Chimeric Mouse/Human IgG1 Antibody Retains Some Effector Function," <u>Hybridoma</u> , 10(2):211-217. | |
| | C243 | Dorai et al., (1992), "Role of Inter-Heavy and Light Chain Disulfide Bonds in the Effector Functions of Human IgG1," <u>Molecular Immunology</u> , 29(12):1487-1491. | |
| | C244 | Elliott et al., (1996), "Fine-Structure Epitope Mapping of Antierythropoietin Monoclonal Antibodies Reveals a Model of Recombinant Human Erythropoietin Structure," <u>Blood</u> , 87(7):2702-2713. | |
| | C245 | Gillies et al., (1991), "Targeting Human Cytotoxic T Lymphocytes to Kill Heterologous Epidermal Growth Factor Receptor-Bearing Tumor Cells: Tumor-Infiltrating Lymphocyte/Hormone Receptor/Recombinant Antibody," <u>J. Immunology</u> , 146(3):1067-1071. | |
| | C246 | Handgretinger et al., (1995), "A Phase I Study of Human/Mouse Chimeric Anti-ganglioside GD2 Antibody ch14.18 in Patients with Neuroblastoma," <u>European J. Cancer</u> , 31A(2):261-267. | |
| | C247 | Hurn et al., (1980), "Production of Reagent Antibodies," <u>Methods in Enzymology</u> , 70: 104-142. | |
| | C248 | Isenman et al., (1975), "The Structure and Function of Immunoglobulin Domains: II. The Importance of Interchain Disulfide Bonds and the Possible Role of Molecular Flexibility in the Interaction between Immunoglobulin G and Complement," <u>J. Immunology</u> , 114(6):1726-1729. | |
| | C249 | Lo et al., (1992), "Expression and Secretion of an Assembled Tetrameric CH2-deleted Antibody in <i>E. Coli</i> ," <u>Hum. Antibod. Hybridomas</u> , 3:123-128. | |
| | C250 | Maecker et al., (1997), "DNA Vaccination with Cytokine Fusion Constructs Biases the Immune Response to Ovalbumin," <u>Vaccine</u> , 15(15):1687-1696. | |
| | C251 | Mueller et al., (1990), "Enhancement of Antibody-Dependent Cytotoxicity With A Chimeric Anti-GD2 Antibody," <u>J. Immunology</u> , 144(4):1382-1386. | |
| | C252 | Mueller et al., (1990), "Serum Half-Life and Tumor Localization of a Chimeric Antibody Deleted of the CH2 Domain and Directed Against the Disialoganglioside GD2," <u>Proc. Natl. Acad. Sci. USA</u> , 87:5702-5705. | |
| | C253 | Naramura et al., (1993), "Therapeutic Potential of Chimeric and Murine Anti-(Epidermal Growth Factor Receptor) Antibodies in a Metastasis Model for Human Melanoma," <u>Cancer Immuno. Immunother.</u> , 37:343-349. | |
| | C254 | Reisfeld et al., (1994), "Potential of Genetically Engineered Anti-Ganglioside GD2 Antibodies for Cancer Immunotherapy," <u>Prog. Brain Res.</u> , 101:201-212. | |
| | C255 | Saleh et al., (1992), "Phase I Trial of the Chimeric Anti-GD2 Monoclonal Antibody ch14.18 in Patients With Malignant Melanoma," <u>Hum. Antibod. Hybridomas</u> , 3:19-24. | |
| | C256 | Sallusto et al., (1994), "Efficient Presentation of Soluble Antigen by Cultured Human Dendritic Cells Is Maintained by Granulocyte/Macrophage Colony-stimulating Factor Plus Interleukin 4 and Downregulated by Tumor Necrosis Factor α ," <u>J. Exp. Med.</u> , 179:1109-1118. | |
| EXAMINER | PbT | | DATE CONSIDERED 2/1/0 |

| | | | |
|--|--|--|------------------------|
| FORM PTO - 1449 | | ATTORNEY DOCKET NO.: LEX-004C1 | |
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT | | APPLICANT: Gillies | |
| | | SERIAL NO.: 10/714,165 | |
| | | FILING DATE: November 14, 2003 GROUP: 1641 | |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| P66 | C257 | Schlom (1991), "Monoclonal Antibodies: They're More and Less Than You Think," in <u>Molecular Foundations of Oncology</u> , pp. 95-133. | |
| | C258 | Wen et al., (1994), "Erythropoietin Structure-Function Relationships: Identification of Functionally Important Domains," <u>J. Biological Chemistry</u> , 269(36):22839-22846. | |
| | C259 | International Preliminary Examination Report for Patent Application Serial No. PCT/US99/08335, mailed on July 31, 2000, 11 pages. | |
| | C260 | International Search Report for Patent Application Serial No. PCT/US99/08335, mailed on October 8, 1999, 4 pages. | |
| | C261 | Written Opinion for Patent Application Serial No. PCT/US99/08335, mailed on April 28, 2000, 7 pages. | |
| EXAMINER |  | | DATE CONSIDERED 2/1/06 |

3092206

FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT



ATTORNEY DOCKET NO.: LEX-004C1

APPLICANT(S): Gillies

SERIAL NO.: 10/714,165

CONF. NO.: 2258

FILING DATE: November 14, 2003

GROUP: 1641

U.S. PATENT DOCUMENTS

| EXAM. INIT. | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
|----------------|-----|--------------------|----------|-------------------|-------|--------------|-------------------------------|
| P6T | A1 | 07/348,237 | 5/5/89 | Rosenblum et al. | | | |
| | A2 | 4,196,265 | 4/1/80 | Koprowski et al. | | | |
| | A3 | 4,469,797 | 9/4/84 | Albarella | | | |
| | A4 | 4,676,980 | 6/30/87 | Segal et al. | | | |
| | A5 | 4,703,008 | 10/27/87 | Lin | | | |
| | A6 | 4,816,567 | 3/28/89 | Cabilly et al. | | | |
| | A7 | 4,946,778 | 8/7/90 | Ladner et al. | | | |
| | A8 | 5,019,368 | 5/28/91 | Epstein et al. | | | |
| | A9 | 5,073,627 | 12/17/91 | Curtis et al. | | | |
| | A10 | 5,114,711 | 5/19/92 | Bell et al. | | | |
| | A11 | 5,116,964 | 5/26/92 | Capon et al. | | | |
| | A12 | 5,199,942 | 4/6/93 | Gillis | | | |
| | A13 | 5,225,538 | 7/6/93 | Capon et al. | | | |
| | A14 | 5,225,539 | 7/6/93 | Winter | | | |
| | A15 | 5,258,498 | 11/2/93 | Huston et al.. | | | |
| | A16 | 5,314,995 | 5/24/94 | Fell, Jr. et al. | | | |
| | A17 | 5,349,053 | 9/20/94 | Landolfi | | | |
| | A18 | 5,359,035 | 10/25/94 | Habermann | | | |
| | A19 | 5,441,868 | 8/15/95 | Lin | | | |
| | A20 | 5,457,038 | 10/10/95 | Trinchieri et al. | | | |
| | A21 | 5,514,582 | 5/7/96 | Capon et al. | | | |
| | A22 | 5,538,866 | 7/23/96 | Israeli et al. | | | |
| | A23 | 5,541,087 | 7/30/96 | Lo et al. | | | |
| | A24 | 5,543,297 | 8/6/96 | Cromlish, et al. | | | |
| | A25 | 5,547,933 | 8/20/96 | Lin | | | |
| | A26 | 5,552,524 | 09/03/96 | Basinski et al. | | | |
| | A27 | 5,585,089 | 12/17/96 | Queen et al. | | | |
| | A28 | 5,609,846 | 3/11/97 | Goldenberg | | | |
| EXAMINER | | | | DATE CONSIDERED | | | |

P6T

2/1/06

| FORM PTO - 1449 | | | | ATTORNEY DOCKET NO.: LEX-004C1 | | | |
|---|-----|--------------------|----------|---------------------------------------|-------|------------------------|-------------------------------|
| INFORMATION DISCLOSURE STATEMENT | | | | APPLICANT(S): Gillies | | | |
| | | | | SERIAL NO.: 10/714,165 | | CONF. NO.: 2258 | |
| | | | | FILING DATE: November 14, 2003 | | GROUP: 1641 | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAM. INIT. | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
| PbT | A29 | 5,618,698 | 4/8/97 | Lin | | | |
| | A30 | 5,624,821 | 4/29/97 | Winter et al. | | | |
| | A31 | 5,639,725 | 6/17/97 | O'Reilly et al. | | | |
| | A32 | 5,645,835 | 7/8/97 | Fell, Jr. et al. | | | |
| | A33 | 5,650,150 | 7/22/97 | Gillies | | | |
| | A34 | 5,650,492 | 7/22/97 | Gately et al. | | | |
| | A35 | 5,667,776 | 9/16/97 | Zimmerman et al. | | | |
| | A36 | 5,679,543 | 10/21/97 | Lawlis | | | |
| | A37 | 5,688,679 | 11/18/97 | Powell | | | |
| | A38 | 5,691,309 | 11/25/97 | Basinski et al. | | | |
| | A39 | 5,709,859 | 1/20/98 | Aruffo et al. | | | |
| | A40 | 5,719,266 | 02/17/98 | DiMarchi et al. | | | |
| | A41 | 5,723,125 | 3/3/98 | Chang et al. | | | |
| | A42 | 5,726,044 | 3/10/98 | Lo et al. | | | |
| | A43 | 5,728,552 | 3/17/98 | Fujisawa et al. | | | |
| | A44 | 5,733,876 | 3/31/98 | O'Reilly et al. | | | |
| | A45 | 5,756,349 | 5/26/98 | Lin | | | |
| | A46 | 5,756,461 | 05/26/98 | Stephens | | | |
| | A47 | 5,759,551 | 6/2/98 | Ladd et al. | | | |
| | A48 | 5,770,195 | 6/23/98 | Hudziak et al. | | | |
| | A49 | 5,800,810 | 9/1/98 | Doyle et al. | | | |
| | A50 | 5,807,715 | 9/15/98 | Morrison et al. | | | |
| | A51 | 5,827,516 | 10/27/98 | Urban et al. | | | |
| | A52 | 5,837,682 | 11/17/98 | Folkman et al. | | | |
| | A53 | 5,843,423 | 12/1/98 | Lyman et al. | | | |
| | A54 | 5,854,205 | 12/29/98 | O'Reilly et al. | | | |
| | A55 | 5,856,298 | 1/5/99 | Strickland | | | |
| | A56 | 5,858,347 | 1/12/99 | Bauer et al. | | | |
| EXAMINER | | | | DATE CONSIDERED | | | |

| FORM PTO - 1449 | | | | ATTORNEY DOCKET NO.: LEX-004C1 | | | |
|---|-----|--------------------|----------|---------------------------------------|-------|------------------------|-------------------------------|
| INFORMATION DISCLOSURE STATEMENT | | | | APPLICANT(S): Gillies | | | |
| | | | | SERIAL NO.: 10/714,165 | | CONF. NO.: 2258 | |
| | | | | FILING DATE: November 14, 2003 | | GROUP: 1641 | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAM. INIT. | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
| P61 | A57 | 5,885,795 | 3/23/99 | O'Reilly et al. | | | |
| | A58 | 5,886,178 | 3/23/99 | Allen et al. | | | |
| | A59 | 5,888,772 | 3/30/99 | Okasinski et al. | | | |
| | A60 | 5,908,626 | 6/1/99 | Chang et al. | | | |
| | A61 | 5,922,685 | 7/13/99 | Rakhmilevich et al. | | | |
| | A62 | 5,955,422 | 9/21/99 | Lin | | | |
| | A63 | 5,994,126 | 11/30/99 | Steinman et al. | | | |
| | A64 | 6,080,409 | 6/27/00 | Laus et al. | | | |
| | A65 | 6,086,875 | 7/11/00 | Blumberg et al. | | | |
| | A66 | 6,100,387 | 8/8/00 | Herrmann et al. | | | |
| | A67 | 6,169,070 | 1/2/01 | Chen et al. | | | |
| | A68 | 6,171,588 | 1/9/01 | Carron et al. | | | |
| | A69 | 6,231,536 | 5/15/01 | Lentz | | | |
| | A70 | 6,277,375 | 8/21/01 | Ward | | | |
| | A71 | 6,284,536 | 9/4/01 | Morrison et al. | | | |
| | A72 | 6,335,176 | 1/1/02 | Inglese et al. | | | |
| | A73 | 6,340,742 | 1/22/02 | Burg et al. | | | |
| | A74 | 6,348,192 | 2/19/02 | Chan et al. | | | |
| | A75 | 6,406,689 | 6/18/02 | Falkenberg et al. | | | |
| | A76 | 6,444,792 | 9/3/02 | Gray et al. | | | |
| | A77 | 6,475,717 | 11/5/02 | Enssle et al. | | | |
| | A78 | 6,485,726 | 11/26/02 | Blumberg et al. | | | |
| | A79 | 6,506,405 | 1/14/03 | Desai et al. | | | |
| | A80 | 6,583,272 | 6/24/03 | Bailon | | | |
| | A81 | 6,586,398 | 7/1/03 | Kinstler et al. | | | |
| | A82 | 6,617,135 | 9/9/03 | Gillies et al. | | | |
| | A83 | 2001/0053539 | 12/20/01 | Lauffer et al. | | | |
| | A84 | 2002/0081664 | 6/27/02 | Lo et al. | | | |
| EXAMINER P61 | | | | DATE CONSIDERED 2/1/6 | | | |

| FORM PTO - 1449 | | | | ATTORNEY DOCKET NO.: LEX-004C1 | | | |
|---|-----|--------------------|----------|---------------------------------------|-------|------------------------|-------------------------------|
| INFORMATION DISCLOSURE STATEMENT | | | | APPLICANT(S): Gillies | | | |
| | | | | SERIAL NO.: 10/714,165 | | CONF. NO.: 2258 | |
| | | | | FILING DATE: November 14, 2003 | | GROUP: 1641 | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAM. INIT. | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
| PBT | A85 | 2002/0142374 | 10/3/02 | Gallo et al. | | | |
| | A86 | 2002/0147311 | 10/10/02 | Gillies et al. | | | |
| | A87 | 2002/0192222 | 12/19/02 | Blumberg et al. | | | |
| | A88 | 2002/0193570 | 12/19/02 | Gillies et al. | | | |
| | A89 | 2003/0003529 | 1/2/03 | Bayer | | | |
| | A90 | 2003/0044423 | 3/6/03 | Gillies et al. | | | |
| | A91 | 2003/0049227 | 3/13/03 | Gillies et al. | | | |
| | A92 | 2003/0105294 | 6/5/03 | Gillies et al. | | | |
| | A93 | 2003/0012789 | 1/6/03 | Blumberg et al. | | | |
| | A94 | 2003/0157054 | 8/21/03 | Gillies et al. | | | |
| | A95 | 2003/0166163 | 9/4/03 | Gillies | | | |
| | A96 | 2003/0166877 | 9/4/03 | Gillies et al. | | | |
| EXAMINER PBT | | | | DATE CONSIDERED 2/1/06 | | | |

| FORM PTO - 1449 | | | | ATTORNEY DOCKET NO.: LEX-004C1 | | | | | |
|---|-----|--------------------|----------|---------------------------------------|------------------------|------------------------|----------------|------------------|--------------------------|
| INFORMATION DISCLOSURE STATEMENT | | | | APPLICANT(S): Gillies | | | | | |
| | | | | SERIAL NO.: 10/714,165 | | CONF. NO.: 2258 | | | |
| | | | | FILING DATE: November 14, 2003 | | GROUP: 1641 | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | |
| EXAM INIT. | | DOCUMENT NUMBER | DATE | COUNTRY CODE | CLASS | SUB CLASS | FILING DATE | ABSTRACT ONLY | ENGLISH LANG (Y/N) |
| PE | B1 | 0 158 198 A1 | 10/16/85 | EP | | | | | Y |
| | B2 | 0 211 769 A2 | 2/25/87 | EP | | | | | Y |
| | B3 | 0 256 714 A2 | 2/24/88 | EP | | | | | Y |
| | B4 | 0 294 703 A2 | 12/14/88 | EP | | | | | Y |
| | B5 | 0 308 936 B1 | 3/29/89 | EP | | | | | Y |
| | B6 | 0 314 317 B1 | 5/3/89 | EP | | | | | Y |
| | B7 | 0 318 554 B1 | 6/7/89 | EP | | | | | Y |
| | B8 | 0 319 012 A2 | 6/7/89 | EP | | | | | Y |
| | B9 | 0 326 120 B1 | 8/2/89 | EP | | | | | Y |
| | B10 | 0 350 230 A2 | 1/10/90 | EP | | | | | Y |
| | B11 | 0 375 562 B1 | 6/27/90 | EP | | | | | Y |
| | B12 | 0 396 387 A2 | 11/7/90 | EP | | | | | Y |
| | B13 | 0 439 095 A2 | 7/31/91 | EP | | | | | Y |
| | B14 | 0 511 747 A1 | 11/4/92 | EP | | | | | Y |
| | B15 | 0 601 043 B1 | 6/15/94 | EP | | | | | Y |
| | B16 | 0 640 619 A1 | 3/1/95 | EP | | | | | Y |
| | B17 | 0 668 353 A1 | 8/23/95 | EP | | | | | Y |
| | B18 | 0 706 799 A2 | 4/17/96 | EP | | | | | Y |
| | B19 | 0 790 309 A1 | 8/20/97 | EP | | | | | Y |
| | B20 | 1 088 888 A1 | 4/4/01 | EP | | | | | Y |
| | B21 | 21725/88 | 3/23/89 | AU | | | | | Y |
| | B22 | 93100115.3 | 7/14/93 | CN | | | | | N |
| | B23 | 93100115.3 | 7/14/93 | CN | | | | Y | Y |
| | B24 | 37 12985 A1 | 11/2/88 | DE | | | | | N |
| | B25 | 37 12985 | 11/2/88 | DE | | | | Y | Y |
| | B26 | 2 292 382 A | 2/21/96 | GB | | | | | Y |
| | B27 | 63-267278 | 11/4/88 | JP | | | | | N |
| EXAMINER | | | | | DATE CONSIDERED | | | | |

FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-004C1

APPLICANT(S): Gillies

SERIAL NO.: 10/714,165

CONF. NO.: 2258

FILING DATE: November 14, 2003 GROUP: 1641

FOREIGN PATENT DOCUMENTS

| EXAM INIT. | | DOCUMENT NUMBER | DATE | COUNTRY CODE | CLASS | SUB CLASS | FILING DATE | ABSTRACT ONLY | ENGLISH LANG (Y/N) |
|--------------------|-----|--------------------|----------|-----------------|-------------------------------|--------------|----------------|---|--------------------------|
| B6T | B28 | 63-267278 | 11/4/88 | JP | | | | Y | Y |
| | B29 | 63-267296 | 11/4/88 | JP | | | | | N |
| | B30 | 63-267296 | 11/4/88 | JP | | | | Y | Y |
| | B31 | 0 237 019 A2 | 9/16/87 | EP | | | | English counterpart of JP 63- 267296 | Y |
| | B32 | WO 86/01533 | 3/13/86 | PCT | | | | | Y |
| | B33 | WO 88/00052 | 1/14/88 | PCT | | | | | Y |
| | B34 | WO 88/09344 | 12/1/88 | PCT | | | | | Y |
| | B35 | WO 89/02922 | 4/6/89 | PCT | | | | | Y |
| | B36 | WO 89/09620 | 10/19/89 | PCT | | | | Abstract in English | N |
| | B37 | WO 90/03801 | 4/19/90 | PCT | | | | | Y |
| | B38 | WO 91/00360 | 1/10/91 | PCT | | | | | Y |
| | B39 | WO 91/04329 | 04/04/91 | PCT | | | | | Y |
| | B40 | WO 91/08298 | 6/13/91 | PCT | | | | | Y |
| | B41 | WO 91/13166 | 9/5/91 | PCT | | | | | Y |
| | B42 | WO 91/14438 | 10/3/91 | PCT | | | | | Y |
| | B43 | WO 92/02240 | 2/20/92 | PCT | | | | | Y |
| | B44 | WO 92/08495 | 5/29/92 | PCT | | | | | Y |
| | B45 | WO 92/08801 | 5/29/92 | PCT | | | | | Y |
| | B46 | WO 92/16562 | 10/1/92 | PCT | | | | | Y |
| | B47 | WO 93/03157 | 2/18/93 | PCT | | | | | Y |
| | B48 | WO 93/10229 | 5/27/93 | PCT | | | | | Y |
| | B49 | WO 94/24160 | 10/27/94 | PCT | | | | | Y |
| | B50 | WO 94/25055 | 11/10/94 | PCT | | | | | Y |
| | B51 | WO 95/05468 | 2/23/95 | PCT | | | | | Y |
| | B52 | WO 95/21258 | 8/10/95 | PCT | | | | | Y |
| | B53 | WO 95/28427 | 10/26/95 | PCT | | | | | Y |
| EXAMINER <i>PO</i> | | | | | DATE CONSIDERED <i>2/1/16</i> | | | | |

| FORM PTO - 1449 | | | | ATTORNEY DOCKET NO.: LEX-004C1 | | | | | |
|----------------------------------|-----|--------------------|----------|--------------------------------|-----------------|-----------------|----------------|------------------|--------------------------|
| INFORMATION DISCLOSURE STATEMENT | | | | APPLICANT(S): Gillies | | | | | |
| | | | | SERIAL NO.: 10/714,165 | | CONF. NO.: 2258 | | | |
| | | | | FILING DATE: November 14, 2003 | | GROUP: 1641 | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | |
| EXAM INIT. | | DOCUMENT NUMBER | DATE | COUNTRY CODE | CLASS | SUB CLASS | FILING DATE | ABSTRACT ONLY | ENGLISH LANG (Y/N) |
| P68 | B54 | WO 95/31483 | 11/23/95 | PCT | | | | | Y |
| | B55 | WO 96/04388 | 02/15/96 | PCT | | | | | Y |
| | B56 | WO 96/05309 | 2/22/96 | PCT | | | | | Y |
| | B57 | WO 96/08570 | 3/21/96 | PCT | | | | | Y |
| | B58 | WO 96/18412 | 6/20/96 | PCT | | | | | Y |
| | B59 | WO 96/31526 | 10/10/96 | PCT | | | | | Y |
| | B60 | WO 97/00317 | 1/3/97 | PCT | | | | | Y |
| | B61 | WO 97/00319 | 1/3/97 | PCT | | | | | Y |
| | B62 | WO 97/15666 | 5/1/97 | PCT | | | | | Y |
| | B63 | WO 97/20062 | 6/5/97 | PCT | | | | | Y |
| | B64 | WO 97/24137 | 7/10/97 | PCT | | | | | Y |
| | B65 | WO 97/24440 | 7/10/97 | PCT | | | | | Y |
| | B66 | WO 97/26335 | 7/24/97 | PCT | | | | | Y |
| | B67 | WO 97/30089 | 8/21/97 | PCT | | | | | Y |
| | B68 | WO 97/33617 | 9/18/97 | PCT | | | | | Y |
| | B69 | WO 97/33619 | 9/18/97 | PCT | | | | | Y |
| | B70 | WO 97/34631 | 9/25/97 | PCT | | | | | Y |
| | B71 | WO 97/43316 | 11/20/97 | PCT | | | | | Y |
| | B72 | WO 98/00127 | 1/8/98 | PCT | | | | | Y |
| | B73 | WO 98/06752 | 2/19/98 | PCT | | | | | Y |
| | B74 | WO 98/28427 | 7/2/98 | PCT | | | | | Y |
| | B75 | WO 98/30706 | 7/16/98 | PCT | | | | | Y |
| | B76 | WO 98/46257 | 10/22/98 | PCT | | | | | Y |
| | B77 | WO 98/59244 | 12/30/98 | PCT | | | | | Y |
| | B78 | WO 99/02709 | 01/21/99 | PCT | | | | | Y |
| | B79 | WO 99/03887 | 01/28/99 | PCT | | | | | Y |
| | B80 | WO 99/29732 | 6/17/99 | PCT | | | | | Y |
| EXAMINER | | | | | DATE CONSIDERED | | | | |

POM

2/1/6

FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-004C1

APPLICANT(S): Gillies

SERIAL NO.: 10/714,165

CONF. NO.: 2258

FILING DATE: November 14, 2003 GROUP: 1641

FOREIGN PATENT DOCUMENTS

| EXAM INIT. | | DOCUMENT NUMBER | DATE | COUNTRY CODE | CLASS | SUB CLASS | FILING DATE | ABSTRACT ONLY | ENGLISH LANG (Y/N) |
|--------------------|------|--------------------|----------|-----------------|------------------------------|--------------|----------------|------------------|--------------------------|
| PBT | B81 | WO 99/43713 | 9/2/99 | PCT | | | | | Y |
| | B82 | WO 99/52562 | 10/21/99 | PCT | | | | | Y |
| | B83 | WO 99/53958 | 10/28/99 | PCT | | | | | Y |
| | B84 | WO 99/60128 | 11/25/99 | PCT | | | | | Y |
| | B85 | WO 99/62944 | 12/09/99 | PCT | | | | | Y |
| | B86 | WO 99/66054 | 12/23/99 | PCT | | | | | Y |
| | B87 | WO 00/11033 | 3/2/00 | PCT | | | | | Y |
| | B88 | WO 00/24893 | 5/4/00 | PCT | | | | | |
| | B89 | WO 00/34317 | 06/15/00 | PCT | | | | | Y |
| | B90 | WO 00/40615 | 7/13/00 | PCT | | | | | Y |
| | B91 | WO 00/68376 | 11/16/00 | PCT | | | | | Y |
| | B92 | WO 00/69913 | 11/23/00 | PCT | | | | | Y |
| | B93 | WO 00/78334 | 12/28/00 | PCT | | | | | Y |
| | B94 | WO 01/07081 | 2/1/01 | PCT | | | | | Y |
| | B95 | WO 01/10912 | 2/15/01 | PCT | | | | | Y |
| | B96 | WO 01/36489 | 5/25/01 | PCT | | | | | Y |
| | B97 | WO 01/58957 | 8/16/01 | PCT | | | | | |
| | B98 | WO 02/02143 | 1/10/02 | PCT | | | | | |
| | B99 | WO 02/066514 | 8/29/02 | PCT | | | | | Y |
| | B100 | WO 02/072605 | 9/19/02 | PCT | | | | | |
| | B101 | WO 02/079232 | 10/10/02 | PCT | | | | | |
| | B102 | WO 02/079415 | 10/10/02 | PCT | | | | | |
| | B103 | WO 02/090566 | 11/14/02 | PCT | | | | | |
| | B104 | WO 03/015697 | 2/27/03 | PCT | | | | | Y |
| | B105 | WO 03/048334 | 6/12/03 | PCT | | | | | |
| | B106 | WO 03/077834 | 9/25/03 | PCT | | | | | Y |
| EXAMINER <i>Pb</i> | | | | | DATE CONSIDERED <i>2/1/6</i> | | | | |

| | | | |
|----------------------------------|--|---|-----------------|
| FORM PTO - 1449 | | ATTORNEY DOCKET NO.: LEX-004C1 | |
| INFORMATION DISCLOSURE STATEMENT | | APPLICANT(S): Gillies | |
| | | SERIAL NO.: 10/714,165 | CONF. NO.: 2258 |
| | | FILING DATE: November 14, 2003 GROUP: 1641 | |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| P69 | C1 | Abaza et al., (1992), "Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization: Demonstration with Region 94-100 (Antigenic Site 3) of Myoglobin," <u>Journal of Protein Chemistry</u> , 11(5):433-444. | |
| | C2 | Abstract XP-002116766, Lupulescu, (1996), "Prostaglandins, Their Inhibitors and Cancer," <u>Prostaglandins, Leukotrienes and Essential Fatty Acids</u> , 54(2):83-94. | |
| | C3 | Afonso et al., (1994), "The Adjuvant Effect of Interleukin-12 in a Vaccine Against Leishmania Major," <u>Science</u> , 263:235-237. | |
| | C4 | Angal et al., (1993), "A Single Amino Acid Substitution Abolishes the Heterogeneity of Chimeric Mouse/Human (IgG4) Antibody," <u>Molecular Immunology</u> , 30(1):105-108. | |
| | C5 | Arenberg et al., (1996), "Interferon- γ -inducible Protein 10 (IP-10) is an Angiostatic Factor that Inhibits Human Non-small Cell Lung Cancer (NSCLC) Tumorigenesis and Spontaneous Metastases," <u>J. Exp. Med.</u> , 184:981-992. | |
| | C6 | Bacha et al., (1988), "Interleukin 2 Receptor-Targeted Cytotoxicity: Interleukin 2 Receptor-mediated Action of a Diphtheria Toxin-related Interleukin 2 Fusion Protein," <u>J. Exp. Med.</u> , 167:612-622. | |
| | C7 | Bachelot et al., (1998), "Retrovirus-Mediated Gene Transfer of an Angiostatin-Endostatin Fusion Protein with Enhanced Anti-Tumor Properties In Vivo," <u>Proceedings of the Annual Meeting of the American Association for Cancer Research</u> , 39:271, Abstract #1856 (XP-002089298). | |
| | C8 | Barnett et al., (1994), "Purification, Characterization and Selective Inhibition of Human Prostaglandin G/H Synthase 1 and 2 Expressed in the Baculovirus System," <u>Biochimica et Biophysica Acta</u> , 1209:130-139. | |
| | C9 | Baselga et al., (1998), "Recombinant Humanized Anti-HER2 Antibody (Herceptin TM) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER3/ <i>neu</i> Overexpressing Human Breast Cancer Xenografts," <u>Cancer Research</u> , 58:2825-2831. | |
| | C10 | Batova et al., (1999), "The Ch14.18-GM-CSF Fusion Protein Is Effective at Mediating Antibody-dependent Cellular Cytotoxicity and Complement-dependent Cytotoxicity in Vitro," <u>Clinical Cancer Research</u> , 5:4259-4263. | |
| | C11 | Batra et al., (1993), "Insertion of Constant Region Domains of Human IgG1 into CD4-PE40 Increases Its Plasma Half-Life," <u>Molecular Immunology</u> , 30(4):379-386. | |
| | C12 | Becker et al., (1996), "An Antibody-Interleukin 2 Fusion Protein Overcomes Tumor Heterogeneity by Induction of a Cellular Immune Response," <u>Proc. Natl. Acad. Sci. USA</u> , 93:7826-7831. | |
| | C13 | Becker et al., (1996), "Eradication of Human Hepatic and Pulmonary Melanoma Metastases in SCID Mice by Antibody-interleukin 2 Fusion Proteins," <u>Proc. Natl. Acad. Sci. USA</u> , 93:2702-2707. | |
| | C14 | Becker et al., (1996), "Long-lived and Transferable Tumor Immunity in Mice after Targeted Interleukin-2 Therapy," <u>J. Clin. Invest.</u> , 98(12):2801-2804. | |
| | C15 | Becker et al., (1996), "T Cell-mediated Eradication of Murine Metastatic Melanoma Induced by Targeted Interleukin-2 Therapy," <u>J. Exp. Med.</u> , 183(50):2361-2366. | |
| EXAMINER | | DATE CONSIDERED | |
| P69 | | 2/1/6 | |

| | | | |
|----------------------------------|--|--|-----------------|
| FORM PTO - 1449 | | ATTORNEY DOCKET NO.: LEX-004C1 | |
| INFORMATION DISCLOSURE STATEMENT | | APPLICANT(S): Gillies | |
| | | SERIAL NO.: 10/714,165 | CONF. NO.: 2258 |
| | | FILING DATE: November 14, 2003 | GROUP: 1641 |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| PbT | C16 | Beutler et al., (1988), "Tumor Necrosis, Cachexia, Shock, and Inflammation: A Common Mediator," <u>Annual Rev. Biochem.</u> , 57:505-518. | |
| | C17 | Bissery et al., (1997), "The Taxoids," in <u>Cancer Therapeutics: Experimental and Clinical Agents</u> , Teicher (ed.), pp. 175-193. | |
| | C18 | Bitonti et al., (2002), "Transepithelial Absorption of an Erythropoietin-Fc Fusion Protein After Delivery to the Central Airways," <u>Respiratory Drug Delivery</u> , 8:309-312. | |
| | C19 | Bjorn et al., (1985), "Evaluation of Monoclonal Antibodies for the Development of Breast Cancer Immunotoxins," <u>Cancer Research</u> , 45:1214-1221. | |
| | C20 | Boehm et al., (1997), "Antiangiogenic Therapy of Experimental Cancer Does Not Induce Acquired Drug Resistance," <u>Nature</u> , 390:404-407. | |
| | C21 | Boehm et al., (1998), "Zinc-Binding of Endostatin Is Essential for Its Antiangiogenic Activity," <u>Biochemical and Biophysical Research Communications</u> , 252:190-194. | |
| | C22 | Boissel et al., (1993), "Erythropoietin Structure-Function Relationships: Mutant Proteins that Test a Model of Tertiary Structure," <u>The Journal of Biological Chemistry</u> , 268(21):15983-15993. | |
| | C23 | Briggs et al., (1974), "Hepatic Clearance of Intact and Desialylated Erythropoietin," <u>American Journal of Physiology</u> , 227(6):1385-1388. | |
| | C24 | Brooks et al., (1994), "Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels," <u>Cell</u> , 79:1157-1164. | |
| | C25 | Buchli et al., (1993), "Structural and Biologic Properties of a Human Aspartic Acid-126 Interleukin-2 Analog," <u>Archives of Biochemistry and Biophysics</u> , 307(2):411-415. | |
| | C26 | Burgess et al., (1990), "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-Binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue," <u>Journal of Cell Biology</u> , 111:2129-2138. | |
| | C27 | Canfield et al., (1991), "The Binding Affinity of Human IgG for its High Affinity Fc Receptor is Determined by Multiple Amino Acids in the CH2 Domain and Is Modulated by the Hinge Region," <u>J. Exp. Med.</u> , 173(6):1483-1491. | |
| | C28 | Cao et al., (1996), "Kringle Domains of Human Angiostatin: Characterization of the Anti-Proliferative Activity of Endothelial Cells," <u>The Journal of Biological Chemistry</u> , 271(46):29461-29467. | |
| | C29 | Cao et al., (1997), "Kringle 5 of Plasminogen is a Novel Inhibitor of Endothelial Cell Growth," <u>The Journal of Biological Chemistry</u> , 272(36):22924-22928. | |
| | C30 | Capon et al., (1989), "Designing CD4 Immuno adhesins for AIDS Therapy," <u>Nature</u> , 337:525-531. | |
| | C31 | Caton et al., (1986), "Structural and Functional Implications of a Restricted Antibody Response to a Defined Antigenic Region on the Influenza Virus Hemagglutinin," <u>The EMBO Journal</u> , 5(7):1577-1587. | |
| | C32 | Chan et al., (1991), "Induction of Interferon γ Production by Natural Killer Cell Stimulatory Factor: Characterization of the Responder Cells and Synergy with Other Inducers," <u>J. Exp. Med.</u> , 173: 869-879. | |
| EXAMINER | | DATE CONSIDERED | |

| | | | |
|----------------------------------|--|--|-----------------|
| FORM PTO - 1449 | | ATTORNEY DOCKET NO.: LEX-004C1 | |
| INFORMATION DISCLOSURE STATEMENT | | APPLICANT(S): Gillies | |
| | | SERIAL NO.: 10/714,165 | CONF. NO.: 2258 |
| | | FILING DATE: November 14, 2003 | GROUP: 1641 |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| P6/P | C33 | Chang et al., (1989), "Overview of Interleukin-2 as an Immunotherapeutic Agent," <u>Seminars in Surgical Oncology</u> , 5:385-390. | |
| | C34 | Chang et al., (1996), "A Point Mutation in Interleukin-2 that Alters Ligand Internalization," <u>Journal of Biological Chemistry</u> , 271(23):13349-13355. | |
| | C35 | Chaudhary et al., (1988), "Selective Killing of HIV-infected Cells by Recombinant Human CD4-Pseudomonas Exotoxin Hybrid Protein," <u>Nature</u> , 335:370-372. | |
| | C36 | Chaudhary et al., (1989), "A Recombinant Immunotoxin Consisting of Two Antibody Variable Domains Fused to <i>Pseudomonas</i> Exotoxin," <u>Nature</u> , 339:394-397. | |
| | C37 | Chen et al., (1997), "Eradication of Murine Bladder Carcinoma by Intratumor Injection of a Bicistronic Adenoviral Vector Carrying cDNAs for the IL-12 Heterodimer and Its Inhibition by the IL-12 p40 Subunit Homodimer," <u>Journal of Immunology</u> , 159(1):351-358. | |
| | C38 | Cheon et al., (1994), "High-affinity Binding Sites for Related Fibroblast Growth Factor Ligands Reside Within Different Receptor Immunoglobulin-like Domains," <u>Proc. Natl. Acad. Sci. USA</u> , 91: 989-993. | |
| | C39 | Chuang et al., (1993), "Effect of New Investigational Drug Taxol on Oncolytic Activity and Stimulation of Human Lymphocytes," <u>Gynecologic Oncology</u> , 49:291-298. | |
| | C40 | Chuang et al., (1994), "Alteration of Lymphocyte Microtubule Assembly, Cytotoxicity, and Activation by the Anticancer Drug Taxol," <u>Cancer Research</u> , 54:1286-1291. | |
| | C41 | Cohen et al., (1996), "Human Leptin Characterization," <u>Nature</u> , 382:589. | |
| | C42 | Cole et al., (1997), "Human IgG2 Variants of Chimeric Anti-CD3 Are Nonmitogenic to T Cells," <u>Journal of Immunology</u> , 159:3613-3621. | |
| | C43 | Collins et al., (1988), "Identification of Specific Residues of Human Interleukin 2 That Affect Binding to the 70-kDa Subunit (p70) of the Interleukin 2 Receptor," <u>Proc. Natl. Acad. Sci. USA</u> , 85:7709-7713. | |
| | C44 | Colombo et al., (1996), "Amount of Interleukin 12 Available at the Tumor Site is Critical for Tumor Regression," <u>Cancer Research</u> , 56:2531-2534. | |
| | C45 | Cruse et al., (eds.), (1995), <u>Illustrated Dictionary of Immunology</u> , pp.156-157, CRC Press, NY. | |
| | C46 | D'Amato et al., (1994), "Thalidomide is an Inhibitor of Angiogenesis," <u>Proc. Natl. Acad. Sci. USA</u> , 91:4082-4085. | |
| | C47 | D'Andrea et al., (1992), "Production of Natural Killer Cell Stimulatory Factor (Interleukin 12) by Peripheral Blood Mononuclear Cells," <u>J. Exp. Med.</u> , 176:1387-1398. | |
| | C48 | Darling et al., (2002), "Glycosylation of Erythropoietin Affects Receptor Binding Kinetics: Role of Electrostatic Interactions," <u>Biochemistry</u> , 41:14524-14531. | |
| | C49 | Davis et al., (2003), "Immunocytokines: Amplification of Anti-cancer Immunity," <u>Cancer Immunol. Immunother.</u> , 52:297-308. | |
| | C50 | Ding et al., (1988), "Zinc-Dependent Dimers Observed in Crystals of Human Endostatin," <u>Proc. Natl. Acad. Sci. USA</u> , 95:10443-10448. | |
| EXAMINER | | DATE CONSIDERED | |
| P6 | | 2/1/6 | |


| | | | |
|----------------------------------|--|---|-----------------------|
| FORM PTO - 1449 | | ATTORNEY DOCKET NO.: LEX-004C1 | |
| INFORMATION DISCLOSURE STATEMENT | | APPLICANT(S): Gillies | |
| | | SERIAL NO.: 10/714,165 | CONF. NO.: 2258 |
| | | FILING DATE: November 14, 2003 | GROUP: 1641 |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| Pb | C51 | Dolman et al., (1998), "Suppression of Human Prostate Carcinoma Metastases in Severe Combined Immunodeficient Mice by Interleukin 2 Immunocytokine Therapy," <u>Clin. Cancer Research.</u> , 4(10):2551-2557. | |
| | C52 | Duncan et al., (1988), "The Binding Site for C1q on IgG," <u>Nature</u> , 332:738-740. | |
| | C53 | Earnest et al., (1992), "Piroxicam and Other Cyclooxygenase Inhibitors: Potential for Cancer Chemoprevention," <u>J. Cell. Biochem. Supp.</u> , 161:156-166. | |
| | C54 | Egrie et al., (2001), "Development and Characterization of Novel Erythropoiesis Stimulating Protein (NESP)," <u>Nephrol. Dial. Transplant.</u> , 16(Supp 3):3-13. | |
| | C55 | Eisenthal, (1990), "Indomethacin Up-regulates the Generation of Lymphokine-Activated Killer-cell Activity and Antibody-dependent Cellular Cytotoxicity Mediated by Interleukin-2," <u>Cancer Immunol. Immunother.</u> , 31:342-348. | |
| | C56 | Elliott et al., (1997), "Mapping of the Active Site of Recombinant Human Erythropoietin," <u>Blood</u> , 89(2):493-502. | |
| | C57 | Fell et al., (1991), "Genetic Construction and Characterization of A Fusion Protein Consisting of a Chimeric F(ab') with Specificity for Carcinomas and Human IL-2," <u>J. Immunology</u> , 146(7):2446-2452. | |
| | C58 | Fell et al., (1992), "Chimeric L6 Anti-tumor Antibody: Genomic Construction, Expression, and Characterization of the Antigen Binding Site," <u>J. Biological Chemistry</u> , 267:15552-15558. | |
| | C59 | Fibi et al., (1995), "N- and O-Glycosylation Muteins of Recombinant Human Erythropoietin Secreted From BHK-21 Cells," <u>Blood</u> , 85(5):1229-1236. | |
| | C60 | Friedman et al., (1998), "Leptin and the Regulation of Body Weight in Mammals," <u>Nature</u> , 395:763-770. | |
| | C61 | Frost et al., (1997), "A Phase I/IB Trial of Murine Monoclonal Anti-GD2 Antibody 14.G2a Plus Interleukin-2 in Children with Refractory Neuroblastoma," <u>Cancer</u> , 80(2):317-333. | |
| | C62 | Gan et al., (1999), "Specific Enzyme-linked Immunosorbent Assays for Quantitation of Antibody-cytokine Fusion Proteins," <u>Clinical and Diagnostic Laboratory Immunology</u> , 6(2):236-42. | |
| | C63 | Gasson et al., (1984), "Purified Human Granulocyte Macrophage Colony-Stimulating Factor: Direct Action on Neutrophils," <u>Science</u> , 226:1339-1342. | |
| | C64 | Gately et al., (1998), "The Interleukin-12/Interleukin-12-Receptor System: Role in Normal and Pathologic Immune Responses," <u>Annu. Rev. Immunol.</u> , 16:495-521. | |
| | C65 | Gillesen et al., (1995), "Mouse Interleukin-12 (IL-12) p40 Homodimer: A Potent IL-12 Antagonist," <u>Eur. J. Immunol.</u> , 25:200-206. | |
| | C66 | Gillies et al., (1989), "Expression of Human Anti-Tetanus Toxoid Antibody in Transfected Murine Myeloma Cells," <u>Bio/Technology</u> , 7:799-804. | |
| | C67 | Gillies et al., (1989), "High-Level Expression of Chimeric Antibodies Using Adapted cDNA Variable Region Cassettes," <u>J. Immunol. Methods</u> , 125:191-202. | |
| | C68 | Gillies et al., (1990), "Antigen Binding and Biological Activities of Engineered Mutant Chimeric Antibodies with Human Tumor Specificities," <u>Hum. Antibod. Hybridomas</u> , 1(1):47-54. | |
| EXAMINER | | Pb M | DATE CONSIDERED 2/1/6 |

| | | | |
|---|---|---|------------------------|
| FORM PTO - 1449 | | ATTORNEY DOCKET NO.: LEX-004C1 | |
| INFORMATION DISCLOSURE STATEMENT | | APPLICANT(S): Gillies | |
| | | SERIAL NO.: 10/714,165 | CONF. NO.: 2258 |
| | | FILING DATE: November 14, 2003 GROUP: 1641 | |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| 865 | C69 | Gillies et al., (1991), "Expression of Genetically Engineered Immunoconjugates of Lymphotoxin and a Chimeric Anti-ganglioside GD2 Antibody," <u>Hybridoma</u> , 10(3):347-56. | |
| | C70 | Gillies et al., (1992), "Antibody-Targeted Interleukin 2 Stimulates T-Cell Killing of Autologous Tumor Cells," <u>Proc. Natl. Acad. Sci. USA</u> , 89:1428-1432. | |
| | C71 | Gillies et al., (1993), "Biological Activity and <i>In Vivo</i> Clearance of Antitumor Antibody/Cytokine Fusion Proteins," <u>Bioconjugate Chem.</u> , 4(3):230-235. | |
| | C72 | Gillies et al., (1998), "Antibody-IL-12 Fusion Proteins are Effective in SCID Mouse Models of Prostate and Colon Carcinoma Metastases," <u>J. Immunology</u> , 160:6195-6203. | |
| | C73 | Gillies et al., (1999), "Improving the Efficacy of Antibody-Interleukin 2 Fusion Proteins by Reducing Their Interaction with Fc Receptors," <u>Cancer Research</u> , 59:2159-2166. | |
| | C74 | Gillies et al., (2002), "Bi-functional Cytokine Fusion Proteins for Gene Therapy and Antibody-targeted Treatment of Cancer," <u>Cancer Immunol. Immunother.</u> , 51(8):449-60. | |
| | C75 | Gillies et al., (2002), "Improved Circulating Half-life and Efficacy of an Antibody-interleukin 2 Immunocytokine Based on Reduced Intracellular Proteolysis," <u>Clin. Cancer Research</u> , 8(1):210-216. | |
| | C76 | Gillis et al., (1978), "T Cell Growth Factor: Parameters of Production And A Quantitative Microassay for Activity," <u>J. Immunology</u> , 120(6):2027-2032. | |
| | C77 | Goeddel et al., (1986), "Tumor Necrosis Factors: Gene Structure and Biological Activities," <u>Cold Spring Harb. Symp. Quant. Biol.</u> , 51:597-609. | |
| | C78 | Greene et al., (1975), "Neuronal Properties of Hybrid Neuroblastoma X Sympathetic Ganglion Cells," <u>Proc. Natl. Acad. Sci. USA</u> , 72(12):4923-4927. | |
| | C79 | Gren et al., (1983), "A New Type of Leukocytic Interferon," English Translation of <u>Dokl. Akad. Nauk. SSSR</u> , 269(4):986-990. | |
| | C80 | Griffon-Etienne et al., (1999), "Taxane-induced Apoptosis Decompresses Blood Vessels and Lowers Interstitial Fluid Pressure in Solid Tumors: Clinical Implications," <u>Cancer Research</u> , 59:3776-3782. | |
| | C81 | Grimaldi et al., (1989), "The t(5;14) Chromosomal Translocation in a Case of Acute Lymphocytic Leukemia Joins the Interleukin-3 Gene to the Immunoglobulin Heavy Chain Gene," <u>Blood</u> , 73(8):2081-2085. | |
| | C82 | Guyre et al., (1997), "Increased Potency of Fc-receptor-targeted Antigens," <u>Cancer Immunol. Immunother.</u> , 45:146-148. | |
| | C83 | Hammerling et al., (1996), "In Vitro Bioassay for Human Erythropoietin Based on Proliferative Stimulation of an Erythroid Cell Line and Analysis of Carbohydrate-dependent Microheterogeneity," <u>Journal of Pharmaceutical and Biomedical Analysis</u> , 14:1455-1469. | |
| | C84 | Hank et al., (1996), "Activation of Human Effector Cells by a Tumor Reactive Recombinant Anti-ganglioside GD2 Interleukin-2 Fusion Protein (ch14.18-IL2)," <u>Clin Cancer Research</u> , 2(12):1951-1959. | |
| | C85 | Hank et al., (2003), "Determination of Peak Serum Levels and Immune Response to the Humanized Anti-ganglioside Antibody-interleukin-2 Immunocytokine," in <u>Methods in Molecular Medicine, Vol. 85: Novel Anticancer Drug Protocols</u> , Buolamwini et al., (eds.), pp. 123-131, Humana Press Inc., Totowana, NJ. | |
| EXAMINER | | DATE CONSIDERED | |

| | | | |
|---|---|---|------------------------|
| FORM PTO - 1449 | | ATTORNEY DOCKET NO.: LEX-004C1 | |
| INFORMATION DISCLOSURE STATEMENT | | APPLICANT(S): Gillies | |
| | | SERIAL NO.: 10/714,165 | CONF. NO.: 2258 |
| | | FILING DATE: November 14, 2003 GROUP: 1641 | |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| P61 | C86 | Haraguchi, (1994), "Isolation of GD3 Synthase Gene by Expression Cloning of GM3 α -2,8-sialyltransferase cDNA using anti-GD2 Monoclonal Antibody," <u>Proc. Natl. Acad. Sci. USA</u> , 91(22):10455-10459. | |
| | C87 | Harris et al., (1993), "Therapeutic Antibodies - the Coming of Age," <u>Trends in Biotechnology</u> , 11:42-44. | |
| | C88 | Harris, (1995), "Processing of C-terminal Lysine and Arginine Residues of Proteins Isolated from Mammalian Cell Culture," <u>J. Chromatography A</u> , 705:129-134. | |
| | C89 | Harvill et al., (1995), "An IgG3-IL2 Fusion Protein Activates Complement, Binds Fc γ RI, Generates LAK Activity and Shows Enhanced Binding to the High Affinity IL-2R," <u>Immunotechnology</u> , 1:95-105. | |
| | C90 | Harvill et al., (1996), "In Vivo Properties of an IgG3-IL-2 Fusion Protein: A General Strategy for Immune Potentiation," <u>J. Immunology</u> , 157(7):3165-3170. | |
| | C91 | Hazama et al., (1993), "Adjuvant-Independent Enhanced Immune Responses to Recombinant Herpes Simplex Virus Type 1 Glycoprotein D by Fusion with Biologically Active Interleukin-2," <u>Vaccine</u> , 11(6):629-636. | |
| | C92 | He et al., (1998), "Humanization and Pharmacokinetics of a Monoclonal Antibody with Specificity for Both E- and P-Selectin," <u>J. Immunology</u> , 160:1029-1035. | |
| | C93 | Heijnen et al., (1996), "Antigen Targeting to Myeloid-specific Human Fc γ RI/CD64 Triggers Enhanced Antibody Responses in Transgenic Mice," <u>J. Clin. Invest.</u> , 97(2):331-338. | |
| | C94 | Heinzel et al., (1997), "In Vivo Production and Function of IL-12 p40 Homodimers," <u>J. Immunology</u> , 158:4381-4388. | |
| | C95 | Hellstrom et al., (1986), "Antitumor Effects of L6, an IgG2a Antibody that Reacts with Most Human Carcinomas," <u>Proc. Natl. Acad. Sci. USA</u> , 83: 7059-7063. | |
| | C96 | Henkart, (1985), "Mechanism of Lymphocyte-Mediated Cytotoxicity," <u>Ann. Rev. Immunol.</u> , 3:31-58. | |
| | C97 | Herrmann et al., (1989), "Hematopoietic Responses With Advanced Malignancy Treated With Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor," <u>Journal of Clinical Oncology</u> , 7(2):159-167. | |
| | C98 | Hezareh et al., (2001), "Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1," <u>J. Virology</u> , 75(24):12161-12168. | |
| | C99 | Hohenester et al., (1998), "Crystal Structure of the Angiogenesis Inhibitor Endostatin at 1.5 Å Resolution," <u>EMBO Journal</u> , 17(6):1656-1664. | |
| | C100 | Holden et al., (2001), "Augmentation of Anti-Tumor Activity of KS-IL2 Immunocytokine with Chemotherapeutic Agents," <u>Proceedings of the American Association for Cancer Research</u> , 42:683, Abstract No. 3675 (XP-002195344). | |
| | C101 | Holden et al., (2001), "Augmentation of Antitumor Activity of an Antibody-Interleukin 2 Immunocytokine with Chemotherapeutic Agents," <u>Clinical Cancer Research</u> , 7:2862-2869. | |
| | C102 | Hoogenboom et al., (1991), "Construction and Expression of Antibody-tumor Necrosis Factor Fusion Proteins," <u>Molecular Immunology</u> , 28(9):1027-1037. | |
| | C103 | Hoogenboom et al., (1991), "Targeting of Tumor Necrosis Factor to Tumor Cells Secretion by Myeloma Cells of a Genetically Engineered Antibody-Tumor Necrosis Factor Hybrid Molecule," <u>Biochim. and Biophys. Acta</u> , 1096(4):345-354 (Abstract). | |
| EXAMINER | | DATE CONSIDERED | |

| | | | |
|----------------------------------|--|---|-----------------------|
| FORM PTO - 1449 | | ATTORNEY DOCKET NO.: LEX-004C1 | |
| INFORMATION DISCLOSURE STATEMENT | | APPLICANT(S): Gillies | |
| | | SERIAL NO.: 10/714,165 | CONF. NO.: 2258 |
| | | FILING DATE: November 14, 2003 GROUP: 1641 | |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| PUS | C104 | Hornick et al., (1999), "Pretreatment with a Monoclonal Antibody/Interleukin-2 Fusion Protein Directed Against DNA Enhances the Delivery of Therapeutic Molecules to Solid Tumors," <u>Clin. Cancer Research</u> , 5:51-60. | |
| | C105 | Hu et al., (1996), "A Chimeric Lym-1/Interleukin 2 Fusion Protein for Increasing Tumor Vascular Permeability and Enhancing Antibody Uptake," <u>Cancer Research</u> , 56:4998-5004. | |
| | C106 | Huck et al., (1986), "Sequence of a Human Immunoglobulin Gamma 3 Heavy Chain Constant Region Gene: Comparison With the Other Human Cy genes," <u>Nucleic Acids Research</u> , 14(4):1779-1789. | |
| | C107 | Huse et al., (1989), "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," <u>Science</u> , 246:1275-1281. | |
| | C108 | Idusogie et al., (2000), "Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc," <u>J. Immunology</u> , 164(8):4178-4184. | |
| | C109 | Imboden et al., (2001), "The Level of MHC Class I Expression on Murine Adenocarcinoma Can Change the Antitumor Effector Mechanism of Immunocytokine Therapy," <u>Cancer Research</u> , 61(4):1500-7. | |
| | C110 | Ingber et al., (1990), "Synthetic Analogues of Fumagillin that Inhibit Angiogenesis and Suppress Tumour Growth," <u>Nature</u> , 348:555-557. | |
| | C111 | Jones et al., (1986), "Replacing the Complementarity-determining Regions in a Human Antibody with Those from a Mouse," <u>Nature</u> , 321:522-525. | |
| | C112 | Ju et al., (1987), "Structure-Function Analysis of Human Interleukin-2: Identification of Amino Acid Residues for Biological Activity," <u>Journal of Biological Chemistry</u> , 262(12):5723-5731. | |
| | C113 | Jung et al., (1986), "Activation of Human Peripheral Blood Mononuclear Cells by Anti-T3: Killing of Tumor Target Cells Coated with Anti-target-anti-T3 Conjugates," <u>Proc. Natl. Acad. Sci. USA</u> , 83:4479-4483. | |
| | C114 | Junghans et al., (1996), "The Protection Receptor of IgG Catabolism is the B2-microglobulin-containing Neonatal Intestinal Transport Receptor," <u>Proc. Natl. Acad. Sci. USA</u> , 93(11):5512-5516. | |
| | C115 | Kang et al., (1991), "Antibody Redesign by Chain Shuffling from Random Combinatorial Immunoglobulin Libraries," <u>Proc. Natl. Acad. Sci. USA</u> , 88:11120-11123. | |
| | C116 | Kappel et al., (1992), "Regulating Gene Expression in Transgenic Animals," <u>Current Opinion in Biotechnology</u> , 3:548-553 | |
| | C117 | Kato et al., (1997), "Mechanism for the Nonlinear Pharmacokinetics of Erythropoietin in Rats," <u>The Journal of Pharmacology and Experimental Therapeutics</u> , 283:520-527. | |
| | C118 | Kato et al., (1998), "Pharmacokinetics of Erythropoietin in Genetically Anemic Mice," <u>Drug Metabolism and Disposition</u> , 26(2):126-131. | |
| | C119 | Karpovsky et al., (1984), "Production of Target-Specific Effector Cells using Hetero-Cross Linked Aggregate Containing Anti-Target Cell and AntiFcγ Receptor Antibodies," <u>Journal of Experimental Medicine</u> , 160(6):1686-1701. | |
| | C120 | Kendra et al., (1999), "Pharmacokinetics and Stability of the ch14.18-Interleukin-2 Fusion Protein in Mice," <u>Cancer Immunol. Immunother.</u> , 48:219-229. | |
| EXAMINER | PUS | | DATE CONSIDERED 2/1/6 |

| | | | |
|----------------------------------|--|--|-----------------------|
| FORM PTO - 1449 | | ATTORNEY DOCKET NO.: LEX-004C1 | |
| INFORMATION DISCLOSURE STATEMENT | | APPLICANT(S): Gillies | |
| | | SERIAL NO.: 10/714,165 | CONF. NO.: 2258 |
| | | FILING DATE: November 14, 2003 | GROUP: 1641 |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| P61 | C121 | Kim et al., (1997), "An Ovalbumin-IL-12 Fusion Protein is More Effective than Ovalbumin Plus Free Recombinant IL-12 in Inducing a T Helper Cell Type 1-dominated Immune Response and Inhibiting Antigen-Specific IgE Production," <u>J. Immunology</u> , 158(9):4137-4144. | |
| | C122 | Kim et al., (1999), "Cytokine Molecular Adjuvants Modulate Immune Responses Induced by DNA Vaccine Constructs for HIV-1 and SIV," <u>Journal of Interferon and Cytokine Research</u> , 19:77-84. | |
| | C123 | Kitamura et al., (1989), "Establishment and Characterization of a Unique Human Cell Line that Proliferates Dependently on GM-CSF, IL-3, or Erythropoietin," <u>Journal of Cellular Physiology</u> , 140:323-334. | |
| | C124 | Kranz et al., (1984), "Attachment of an Anti-receptor Antibody to Non-target Cells Renders Them Susceptible to Lysis by a Clone of Cytotoxic T Lymphocytes," <u>Proc. Natl. Acad. Sci. USA</u> , 81:7922-7926. | |
| | C125 | Kuo et al., (2001), "Oligomerization-dependent Regulation of Motility and Morphogenesis by the Collagen XVIII NC1/Endostatin Domain," <u>Journal of Cell Biology</u> , 152(6):1233-1246. | |
| | C126 | Kushner et al., (2001), "Phase II Trial of the Anti-GD2 Monoclonal Antibody 3F8 and Granulocyte-Macrophage Colony-Stimulating Factor for Neuroblastoma," <u>J. Clinical Oncology</u> , 19(22):4189-94. | |
| | C127 | LaVallie et al., (1993), "Cloning and Functional Expression of a cDNA Encoding the Catalytic Subunit of Bovine Enterokinase," <u>Journal of Biological Chemistry</u> , 268(31):23311-23317. | |
| | C128 | Lazar et al., (1988), "Transforming Growth Factor α Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities," <u>Molecular and Cellular Biology</u> , 8(3):1247-1252. | |
| | C129 | LeBerthon et al., (1991), "Enhanced Tumor Uptake of Macromolecules Induced by a Novel Vasoactive Interleukin 2 Immunoconjugate," <u>Cancer Research</u> , 51:2694-2698. | |
| | C130 | Lieschke, et al., (1997), "Bioactive Murine and Human Interleukin-12 Fusion Proteins which Retain Antitumor Activity In Vivo," <u>Nature Biotechnology</u> , 15(1):35-40. | |
| | C131 | Linsley et al., (1991), "CTLA-4 is a Second Receptor for B Cell Activation Antigen B7," <u>J. Exp. Med.</u> , 174(3):561-569. | |
| | C132 | Liu et al., (1985), "Heteroantibody Duplexes Target Cells for Lysis by Cytotoxic T Lymphocytes," <u>Proc. Natl. Acad. Sci. USA</u> , 82:8648-8652. | |
| | C133 | Liu et al., (1988), "Hormone Conjugated with Antibody to CD3 Mediates Cytotoxic T Cell Lysis of Human Melanoma Cells," <u>Science</u> , 239:395-398. | |
| | C134 | Liu et al., (1998), "Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor," <u>Blood</u> , 92(10):3730-3736. | |
| | C135 | Lo et al., (1998), "High Level Expression and Secretion of Fc-X Fusion Proteins in Mammalian Cells," <u>Protein Engineering</u> , 11(6):495-500. | |
| | C136 | Locatelli et al., (2001), "Darbepoetin alfa Amgen," <u>Current Opinion in Investigational Drugs</u> , 2:1097-1104. | |
| | C137 | Lode et al., (1997), "Targeted Interleukin-2 Therapy for Spontaneous Neuroblastoma Metastases to Bone Marrow," <u>J. Natl. Cancer Inst.</u> , 89(21):1586-94. | |
| | C138 | Lode et al., (1998), "Immunocytokines: A Promising Approach to Cancer Immunotherapy," <u>Pharmacol. Ther.</u> , 80(3):277-292. | |
| EXAMINER | P667 | | DATE CONSIDERED 2/1/6 |

| | | | |
|----------------------------------|--|--|-----------------------|
| FORM PTO - 1449 | | ATTORNEY DOCKET NO.: LEX-004C1 | |
| INFORMATION DISCLOSURE STATEMENT | | APPLICANT(S): Gillies | |
| | | SERIAL NO.: 10/714,165 | CONF. NO.: 2258 |
| | | FILING DATE: November 14, 2003 | GROUP: 1641 |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| P6T | C139 | Lode et al., (1998), "Natural Killer Cell-Mediated Eradication of Neuroblastoma Metastases to Bone Marrow by Targeted Interleukin-2 Therapy," <u>Blood</u> , 91(5):1706-1715. | |
| | C140 | Lode et al., (1999), "Synergy Between an Antiangiogenic Integrin α_v Antagonist and an Antibody-cytokine Fusion Protein Eradicates Spontaneous Tumor Metastases," <u>Proc. Natl. Acad. Sci. USA</u> , 96:1591-1596. | |
| | C141 | Lode et al., (1999), "Tumor-targeted IL-2 Amplifies T Cell-mediated Immune Response Induced by Gene Therapy with Single-chain IL-12," <u>Proc. Natl. Acad. Sci. USA</u> , 96:8591-8596. | |
| | C142 | Lode et al., (2000), "Amplification of T Cell Mediated Immune Responses by Antibody-Cytokine Fusion Proteins," <u>Immunological Investigations</u> , 29(2):117-120. | |
| | C143 | Lode et al., (2000), "What To Do With Targeted IL-2," <u>Drugs of Today</u> , 36(5):321-336. | |
| | C144 | Lode et al., (2000), "Melanoma Immunotherapy by Targeted IL-2 Depends on CD4(+) T-cell Help Mediated by CD40/CD40L Interaction," <u>J. Clin. Invest.</u> , 105(11):1623-30. | |
| | C145 | Macdougall, (2002), "Optimizing the Use of Erythropoietic Agents—Pharmacokinetic and Pharmacodynamic Considerations," <u>Nephrol. Dial. Transplant.</u> , 17(Supp 5):66-70. | |
| | C146 | Maloney et al., (1994), "Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Patients with Recurrent B-Cell Lymphoma," <u>Blood</u> , 84(8):2457-2466. | |
| | C147 | Mark et al., (1992), "Expression and Characterization of Hepatocyte Growth Factor Receptor-IgG Fusion Proteins," <u>Journal of Biological Chemistry</u> , 267(36):26166-26171. | |
| | C148 | Martinotti et al., (1995), "CD4 T Cells Inhibit <i>In Vivo</i> the CD8-Mediated Immune Response Against Murine Colon Carcinoma Cells Transduced with Interleukin-12 Genes," <u>Eur. J. Immunol.</u> 25:137-146. | |
| | C149 | Medesan et al., (1997), "Delineation of the Amino Acid Residues Involved in Transcytosis and Catabolism of Mouse IgG1," <u>J. Immunology</u> , 158(5):2211-2217. | |
| | C150 | Metelitsa et al., (2002), "Antidisialoganglioside/granulocyte Macrophage-colony-stimulating Factor Fusion Protein Facilitates Neutrophil Antibody-dependent Cellular Cytotoxicity and Depends on Fc γ RII (CD32) and Mac-1 (CD11b/CD18) for Enhanced Effector Cell Adhesion and Azurophil Granule Exocytosis," <u>Blood</u> , 99(11):4166-73. | |
| | C151 | Mestre et al., (1997), "Retinoids Suppress Epidermal Growth Factor-induced Transcription of Cyclooxygenase-2 in Human Oral Squamous Carcinoma Cells," <u>Cancer Research</u> , 57:2890-2895. | |
| | C152 | Mosmann et al., (1989), "TH1 and TH2 Cells: Different Patterns of Lymphokine Secretion Lead to Different Functional Properties," <u>Ann. Rev. Immunol.</u> , 7:145-173. | |
| | C153 | Mott et al., (1995), "The Solution Structure of the F42A Mutant of Human Interleukin 2," <u>J. Mol. Biol.</u> , 247:979-994. | |
| | C154 | Mueller et al., (1997), "Humanized Porcine VCAM-specific Monoclonal Antibodies with Chimeric IgG2/G4 Constant Regions Block Human Leukocyte Binding to Porcine Endothelial Cells," <u>Molecular Immunology</u> , 34(6):441-452. | |
| | C155 | Mullins et al., (1997), "Taxol-mediated Changes in Fibrosarcoma-induced Immune Cell Function: Modulation of Antitumor Activities," <u>Cancer Immunol. Immunother.</u> 45:20-28. | |
| EXAMINER | Pb  | | DATE CONSIDERED 2/1/6 |

| | | | |
|----------------------------------|--|---|-----------------|
| FORM PTO - 1449 | | ATTORNEY DOCKET NO.: LEX-004C1 | |
| INFORMATION DISCLOSURE STATEMENT | | APPLICANT(S): Gillies | |
| | | SERIAL NO.: 10/714,165 | CONF. NO.: 2258 |
| | | FILING DATE: November 14, 2003 | GROUP: 1641 |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| P61 | C156 | Mullins et al., (1998), "Interleukin-12 Overcomes Paclitaxel-mediated Suppression of T-cell Proliferation," <u>Immunopharmacol. Immunotoxicol.</u> , 20(4):473-492. | |
| | C157 | Murphy et al., (1986), "Genetic Construction, Expression, and Melanoma-selective Cytotoxicity of a Diphtheria Toxin-related α -melanocyte-stimulating Hormone Fusion Protein," <u>Proc. Natl. Acad. Sci. USA</u> , 83:8258-8262. | |
| | C158 | Murphy, (1988), "Diphtheria-related Peptide Hormone Gene Fusions: A Molecular Gene Approach to Chimeric Toxin Development," in <u>Immunotoxins</u> , pp. 123-140, Frankel (ed.), Kluwer Acad. Pub. | |
| | C159 | Naramura et al., (1994), "Mechanisms of Cellular Cytotoxicity Mediated by a Recombinant Antibody-IL2 Fusion Protein Against Human Melanoma Cells," <u>Immunology Letters</u> , 39:91-99. | |
| | C160 | Neal et al., (2003), "NXS2 Murine Neuroblastomas Express Increased Levels of MHC Class I Antigens upon Recurrence Following NK-dependent Immunotherapy," <u>Cancer Immunol. Immunother.</u> , 53:41-52. | |
| | C161 | Nedwin et al., (1985), "Human Lymphotoxin and Tumor Necrosis Factor Genes: Structure, Homology and Chromosomal Localization," <u>Nucleic Acids Research</u> , 13(17):6361-6373. | |
| | C162 | Netti et al., (1995), "Time-dependent Behavior of Interstitial Fluid Pressure in Solid Tumors: Implications for Drug Delivery," <u>Cancer Research</u> , 55:5451-5458. | |
| | C163 | Netti et al., (1999), "Enhancement of Fluid Filtration Across Tumor Vessels: Implication for Delivery of Macromolecules," <u>Proc. Nat. Acad. Sci. USA</u> , 96:3137-3142. | |
| | C164 | Neuberger et al., (1984), "Recombinant Antibodies Possessing Novel Effector Functions," <u>Nature</u> , 312:604-608. | |
| | C165 | Ngo et al., (1994), "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," in <u>The Protein Folding Problem and Tertiary Structure Prediction</u> , Merz et al. (eds.), pp. 433-440 and 492-495, Birkhauser, Boston, MA. | |
| | C166 | Niethammer et al., (2002) "An Oral DNA Vaccine Against Human Carcinoembryonic Antigen (CEA) Prevents Growth and Dissemination of Lewis Lung Carcinoma in CEA Transgenic Mice," <u>Vaccine</u> , 20:421-429. | |
| | C167 | Niethammer et al., (2001) "Targeted Interleukin 2 Therapy Enhances Protective Immunity Induced by an Autologous Oral DNA Vaccine against Murine Melanoma," <u>Cancer Research</u> , 61(16):6178-84. | |
| | C168 | Nimtz et al., (1993), "Structures of Sialylated Oligosaccharides of Human Erythropoietin Expressed in Recombinant BHK-21 Cells," <u>Eur. J. Biochem.</u> , 213:39-56. | |
| | C169 | O'Reilly et al., (1994), "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," <u>Cell</u> , 79:315-328. | |
| | C170 | O'Reilly et al., (1996), "Angiostatin Induces and Sustains Dormancy of Human Primary Tumors in Mice," <u>Nature Medicine</u> , 2(6):689-692. | |
| | C171 | O'Reilly et al., (1997), "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth," <u>Cell</u> , 88:277-285. | |
| | C172 | Pancook et al., (1996), "Eradication of Established Hepatic Human Neuroblastoma Metastases in Mice with Severe Combined Immunodeficiency by Antibody-targeted Interleukin-2," <u>Cancer Immunol. Immunother.</u> , 42(2):88-92. | |
| EXAMINER | | DATE CONSIDERED 2/1/06 | |

| | | | |
|----------------------------------|--|---|-----------------|
| FORM PTO - 1449 | | ATTORNEY DOCKET NO.: LEX-004C1 | |
| INFORMATION DISCLOSURE STATEMENT | | APPLICANT(S): Gillies | |
| | | SERIAL NO.: 10/714,165 | CONF. NO.: 2258 |
| | | FILING DATE: November 14, 2003 | GROUP: 1641 |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| Ref | C173 | Park et al., (2000), "Efficiency of Promoter and Cell Line in High-level Expression of Erythropoietin," <u>Biotechnol. Appl. Biochem.</u> , 32:167-172. | |
| | C174 | Pastan et al., (1989), "Pseudomonas Exotoxin: Chimeric Toxins," <u>Journal of Biological Chemistry</u> , 264(26):15157-15160. | |
| | C175 | Paul et al., (1988), "Lymphotoxin," <u>Ann. Rev. Immunol.</u> , 6:407-438. | |
| | C176 | Perez et al., (1986), "Specific Targeting of Human Peripheral Blood T Cells by Heteroaggregates Containing Anti-T3 Crosslinked to Anti-Target Cell Antibodies," <u>J. Exp. Med.</u> , 163:166-178. | |
| | C177 | Perez et al., (1989), "Isolation and Characterization of a cDNA Encoding the KS1/4 Epithelial Carcinoma Marker," <u>J. Immunology</u> , 142(10):3662-3667. | |
| | C178 | Polizzi et al., (1999), "A Novel Taxane with Improved Tolerability and Therapeutic Activity in a Panel of Human Tumor Xenografts," <u>Cancer Research</u> , 59:1036-1040. | |
| | C179 | Putzer et al., (1997), "Interleukin 12 and B7-1 Costimulatory Molecule Expressed by an Adenovirus Vector Act Synergistically to Facilitate Tumor Regression," <u>Proc. Natl. Acad. Sci. USA</u> , 94(20):10889-10894. | |
| | C180 | Reisfeld et al., (1996), "Antibody-interleukin 2 Fusion Proteins: A New Approach to Cancer Therapy," <u>J. Clin. Lab. Anal.</u> , 10:160-166. | |
| | C181 | Reisfeld et al., (1996), "Involvement of B Lymphocytes in the Growth Inhibition of Human Pulmonary Melanoma Metastases in Athymic <i>nu/nu</i> Mice by an Antibody-lymphotoxin Fusion Protein," <u>Cancer Research</u> , 56(8):1707-1712. | |
| | C182 | Reisfeld et al., (1996), "Recombinant Antibody Fusion Proteins for Cancer Immunotherapy," <u>Current Topics in Microbiology and Immunology</u> , 213:27-53. | |
| | C183 | Reisfeld et al., (1997), "Immunocytokines: A New Approach to Immunotherapy of Melanoma," <u>Melanoma Research</u> , 7(Supp2):S99-S106. | |
| | C184 | Riethmuller et al., (1994), "Randomised Trial of Monoclonal Antibody for Adjuvant Therapy of Resected Dukes' C Colorectal Carcinoma," <u>The Lancet</u> , 343:1177-1183. | |
| | C185 | Roessler et al., (1994), "Cooperative Interactions Between the Interleukin 2 Receptor α and β Chains Alter the Interleukin 2-binding Affinity of the Receptor Subunits," <u>Proc. Natl. Acad. Sci. USA</u> , 91:3344-3347. | |
| | C186 | Roitt et al., (1993), "The Role of T _H Cells in the Selection of Effector Mechanisms Directed Against Target Antigens," <u>Immunology</u> , 3 rd Ed., pp. 8.3-8.4. | |
| | C187 | Rosenberg, (1988), "Immunotherapy of Cancer Using Interleukin 2: Current Status and Future Prospects," <u>Immunology Today</u> , 9(2):58-62. | |
| | C188 | Rozwarski et al., (1994), "Structural Comparisons Among the Short-chain Helical Cytokines," <u>Structure</u> , 2(3):159-173. | |
| | C189 | Ruehlmann et al., (2001), "MIG (CIXCL9) Chemokine Gene Therapy Combines with Antibody-cytokine Fusion Protein to Suppress Growth and Dissemination of Murine Colon Carcinoma," <u>Cancer Research</u> , 61(23):8498-503. | |
| EXAMINER | | DATE CONSIDERED | |

Ref

Ph CV

2/1/6

| | | | |
|----------------------------------|--|---|-----------------|
| FORM PTO - 1449 | | ATTORNEY DOCKET NO.: LEX-004C1 | |
| INFORMATION DISCLOSURE STATEMENT | | APPLICANT(S): Gillies | |
| | | SERIAL NO.: 10/714,165 | CONF. NO.: 2258 |
| | | FILING DATE: November 14, 2003 GROUP: 1641 | |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| PKT | C190 | Sabzevari et al., (1994), "A Recombinant Antibody-interleukin 2 Fusion Protein Suppresses Growth of Hepatic Human Severe Combined Immunodeficiency Mice," <u>Proc. Natl. Acad. Sci. USA</u> , 91(20):9626-30. | |
| | C191 | Santon et al., (1986), "Effects of Epidermal Growth Factor Receptor Concentration on Tumorigenicity of A431 Cells in Nude Mice," <u>Cancer Research</u> , 46:4701-4705. | |
| | C192 | Sasaki et al., (1998), "Structure, Function and Tissue Forms of the C-terminal Globular Domain of Collagen XVIII Containing the Angiogenesis Inhibitor Endostatin," <u>EMBO Journal</u> , 17(15):4249-4256. | |
| | C193 | Sauve et al., (1991), "Localization in Human Interleukin 2 of the Binding Site to the α -chain (p55) of the Interleukin 2 Receptor," <u>Proc. Natl. Acad. Sci. USA</u> , 88:4636-4640. | |
| | C194 | Schnee et al., (1987), "Construction and Expression of a Recombinant Antibody-targeted Plasminogen Activator," <u>Proc. Natl. Acad. Sci. USA</u> , 84:6904-6908. | |
| | C195 | Schoenhaut et al., (1992), "Cloning and Expression of Murine IL-12," <u>J. Immunology</u> , 148(11):3433-3440. | |
| | C196 | Seidenfeld et al., (2001), "Epoietin Treatment of Anemia Associated with Cancer Therapy: A Systematic Review and Meta-analysis of Controlled Clinical Trials," <u>Journal of National Cancer Institute</u> , 93(16):1204-1214. | |
| | C197 | Senter et al., (1988), "Anti-tumor Effects of Antibody-alkaline Phosphatase Conjugates in Combination with Etoposide Phosphate," <u>Proc. Natl. Acad. Sci. USA</u> , 85(13):4842-4846. | |
| | C198 | Shanafelt et al., (2000), "A T-cell-Selective Interleukin 2 Mutein Exhibits Potent Antitumor Activity and is Well Tolerated <i>In Vivo</i> ," <u>Nature Biotechnology</u> , 18:1197-1202. | |
| | C199 | Sharma et al., (1999), "T cell-derived IL-10 Promotes Lung Cancer Growth by Suppressing Both T cell and APC Function," <u>Journal of Immunology</u> , 163:5020-5028. | |
| | C200 | Shen et al., (1986), "Heteroantibody-Mediated Cytotoxicity: Antibody to the High Affinity Fc Receptor for IgG Mediates Cytotoxicity by Human Monocytes That is Enhanced by Interferon- γ and is Not Blocked by Human IgG," <u>J. Immunology</u> , 137(11):3378-3382. | |
| | C201 | Shiff et al., (1995), "Sulindac Sulfide, an Aspirin-like Compound, Inhibits Proliferation, Causes Cell Cycle Quiescence, and Induces Apoptosis in HT-29 Colon Adenocarcinoma Cells," <u>Journal of Clinical Investigation</u> , 96:491-503. | |
| | C202 | Shin et al., (1990), "Expression and Characterization of an Antibody Binding Specificity Joined to Insulin-like Growth Factor 1: Potential Applications for Cellular Targeting," <u>Proc. Natl. Acad. Sci. USA</u> , 87:5322-5326. | |
| | C203 | Shinkawa et al., (2003), "The Absence of Fucose But Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity," <u>J. Biol. Chem.</u> , 278:3466-3473. | |
| | C204 | Sim et al., (1997), "A Recombinant Human Angiostatin Protein Inhibits Experimental Primary and Metastatic Cancer," <u>Cancer Research</u> , 57:1329-1334. | |
| | C205 | Spiekermann et al., (2002), "Receptor-mediated Immunoglobulin G Transport Across Mucosal Barriers in Adult Life: Functional Expression of FcRn in the Mammalian Lung," <u>J. Exp. Med.</u> , 196:303-310. | |
| EXAMINER | DATE CONSIDERED | | |

| | | | |
|----------------------------------|--|--|-----------------|
| FORM PTO - 1449 | | ATTORNEY DOCKET NO.: LEX-004C1 | |
| INFORMATION DISCLOSURE STATEMENT | | APPLICANT(S): Gillies | |
| | | SERIAL NO.: 10/714,165 | CONF. NO.: 2258 |
| | | FILING DATE: November 14, 2003 | GROUP: 1641 |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| Pk f | C206 | Stevenson et al., (1997), "Conjugation of Human Fc γ in Closed-Hinge or Open-Hinge Configuration to Fab' γ and Analogous Ligands," <u>J. Immunology</u> , 158:2242-2250. | |
| | C207 | Strom et al., (1996), "Therapeutic Approach to Organ Transplantation," Chapter 36, pp. 451-456, in <u>Therapeutic Immunology</u> , Austen et al., (eds.), Blackwell Science. | |
| | C208 | Sulitzeanu, (1993), "Immunosuppressive Factors in Human Cancer," pp. 247-266 in <u>Advances in Cancer Research</u> , Vol. 60, Vande Woude et al. (eds.), Academic Press, Inc. | |
| | C209 | Syed et al., (1998), "Efficiency of Signaling Through Cytokine Receptors Depends Critically on Receptor Orientation," <u>Nature</u> , 395:511-516. | |
| | C210 | Taniguchi et al., (1983), "Structure and Expression of a Cloned cDNA for Human Interleukin-2," <u>Nature</u> , 302:305-309. | |
| | C211 | Tao et al., (1989), "Studies of Aglycosylated Chimeric Mouse IgG: Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region," <u>J. Immunology</u> , 143(8):2595-2601. | |
| | C212 | Tao et al., (1993), "Structural Features of Human Immunoglobulin G that Determine Isotype-Differences in Complement Activation," <u>J. Exp. Med.</u> , 178(2):661-667. | |
| | C213 | Teicher et al., (1994), "Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and With Other Anti-Angiogenic Agents," <u>Int. J. Cancer</u> , 57:920-925. | |
| | C214 | <u>The Merck Manual of Diagnosis and Therapy</u> , 17 th Ed., (1999) pp. 990-993 and 1278-1283. | |
| | C215 | Thommesen et al., (2000), "Lysine 322 in the Human IgG3 CH2 Domain is Crucial for Antibody Dependent Complement Activation," <u>Mol. Immunol.</u> , 37(16):995-1004. | |
| | C216 | Till et al., (1988), "An Assay that Predicts the Ability of Monoclonal Antibodies to Form Potent Ricin A Chain-containing Immunotoxins," <u>Cancer Research</u> , 48(5):1119-1123 | |
| | C217 | Till et al., (1988), "HIV-Infected Cells are Killed by rCD4-Ricin A Chain," <u>Science</u> , 242:1166-1168. | |
| | C218 | Trinchieri, (1994), "Interleukin-12: A Cytokine Produced by Antigen-Presenting Cells With Immunoregulatory Functions in the Generation of T-Helper Cells Type 1 and Cytotoxic Lymphocytes," <u>Blood</u> , 84:4008-4027. | |
| | C219 | Vagliani et al., (1996), "Interleukin 12 Potentiates the Curative Effect of a Vaccine Based on Interleukin 2-transduced Tumor Cells," <u>Cancer Research</u> , 56:467-470. | |
| | C220 | Varki et al., (1984), "Antigens Associated with a Human Lung Adenocarcinoma Defined by Monoclonal Antibodies," <u>Cancer Research</u> , 44:681-687. | |
| | C221 | Verhoeyen et al., (1988), "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," <u>Science</u> , 239:1534-1536. | |
| | C222 | Villunger et al., (1997), "Constitutive Expression of Fas (Apo-1/CD95) Ligand on Multiple Myeloma Cells: A Potential Mechanism of Tumor-induced Suppression of Immune Surveillance," <u>Blood</u> , 90(1):12-20. | |
| | C223 | Watanabe et al., (1997), "Long-term Depletion of Naive T cells in Patients Treated for Hodgkin's Disease," <u>Blood</u> , 90(9):3662-3672. | |
| | C224 | Wells, (1990), "Additivity of Mutational Effect in Proteins," <u>Biochemistry</u> , 29(37):8509-8517. | |
| EXAMINER | | DATE CONSIDERED | |

Pk f

2/1/6

| | | | |
|----------------------------------|--|--|------------------------|
| FORM PTO - 1449 | | ATTORNEY DOCKET NO.: LEX-004C1 | |
| INFORMATION DISCLOSURE STATEMENT | | APPLICANT(S): Gillies | |
| | | SERIAL NO.: 10/714,165 | CONF. NO.: 2258 |
| | | FILING DATE: November 14, 2003 | GROUP: 1641 |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| P67 | C225 | Wen et al., (1993), "Erythropoietin Structure-Function Relationships: High Degree of Sequence Homology Among Mammals," <u>Blood</u> , 82(5):1507-1516. | |
| | C226 | Williams et al., (1986), "Production of Antibody-tagged Enzymes by Myeloma Cells: Application to DNA Polymerase I Klenow Fragment," <u>Gene</u> , 43:319-324. | |
| | C227 | Williams et al., (1987), "Diphtheria Toxin Receptor Binding Domain Substitution with Interleukin-2: Genetic Construction and Properties of a Diphtheria Toxin-related Interleukin-2 Fusion Protein," <u>Protein Engineering</u> , 1(6):493-498. | |
| | C228 | Wooley et al., (1993), "Influence of a Recombinant Human Soluble Tumor Necrosis Factor Receptor Fc Fusion Protein on Type II Collagen-Induced Arthritis in Mice," <u>J. Immunology</u> , 151:6602-6607. | |
| | C229 | Wu et al., (1997), "Suppression of Tumor Growth with Recombinant Murine Angiostatin," <u>Biochemical and Biophysical Research Communications</u> , 236:651-654. | |
| | C230 | Xiang et al., (1997), "Elimination of Established Murine Colon Carcinoma Metastases by Antibody-Interleukin 2 Fusion Protein Therapy," <u>Cancer Research</u> , 57:4948-4955. | |
| | C231 | Xiang et al., (1998), "Induction of Persistent Tumor-protective Immunity in Mice Cured of Established Colon Carcinoma Metastases," <u>Cancer Research</u> , 58(17):3918-3925. | |
| | C232 | Xiang et al., (1999) "T Cell Memory against Colon Carcinoma is Long-lived in the Absence of Antigen," <u>J. Immunology</u> , 163(7):3676-83. | |
| | C233 | Xiang et al., (2001), "A Dual Function DNA Vaccine Encoding Carcinoembryonic Antigen and CD40 Ligand Trimer Induces T Cell-mediated Protective Immunity Against Colon Cancer in Carcinoembryonic Antigen-Transgenic Mice," <u>J. Immunology</u> , 167(8):4560-5. | |
| | C234 | Xiang et al., (2001), "Protective Immunity Against Human Carcinoembryonic Antigen (CEA) Induced by an Oral DNA Vaccine in CEA-transgenic Mice," <u>Clinical Cancer Research</u> , 7(3 Supp):S856-S864. | |
| | C235 | Xu et al., (1994), "Residue at Position 331 in the IgG1 and IgG4 CH2 Domains Contributes to Their Differential Ability to Bind and Activate Complement," <u>J. Biol. Chem.</u> , 269(5):3469-3474. | |
| | C236 | Yu et al., (1998), "Phase I Trial of a Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 in Patients with Refractory Neuroblastoma and Osteosarcoma," <u>J. Clinical Oncology</u> , 16(6):2169-80. | |
| | C237 | Zagozdzon et al., (1999), "Potentiation of Antitumor Effects of IL-12 in Combination with Paclitaxel in Murine Melanoma Model <i>In Vivo</i> ," <u>International Journal of Molecular Medicine</u> , 4:645-648. | |
| | C238 | Zheng et al., (1995), "Administration of Noncytolytic IL-10/Fc in Murine Models of Lipopolysaccharide-induced Septic Shock and Allogeneic Islet Transplantation," <u>J. Immunology</u> , 154:5590-5600. | |
| EXAMINER | P67 | | DATE CONSIDERED 2/1/06 |

3044892